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ABSTRACT 
The innate immune response is an essential component of the mammalian 
immune system that responds rapidly to pathogens. This response to pathogens 
is initiated by the detection of pathogen associated molecular patterns (PAMPs) 
by pathogen recognition receptors (PRRs). PRR signaling activates antipathogen 
gene programs via transcription factors (TFs) such as the interferon regulatory 
factors (IRFs). IRF3, IRF5, and IRF7 (IRF3/5/7) are key signal-dependent TFs 
that have overlapping, yet distinct, roles in the mammalian response to 
pathogens. To examine the role that DNA-binding specificity plays in delineating 
IRF3/5/7-specific gene regulation, we used protein-binding microarrays (PBMs) 
to characterize the DNA binding of IRF3/5/7 homodimers. We identified both 
common and dimer-specific DNA binding sites, and show that DNA-binding 
differences can translate into dimer-specific gene regulation. Central to the 
antiviral response, IRF3/5/7 regulate type I interferon (IFN) genes. We show that 
IRF3 and IRF7 bind to many interferon-stimulated response element (ISRE)-type 
sites in the virus-response elements (VREs) of IFN promoters. However, 
  vii 
strikingly, IRF5 does not bind the VREs, suggesting evolutionary selection 
against IRF5 homodimer binding. Mutational analysis identified a a critical 
specificity-determining residue that inhibits IRF5 binding to the ISRE-variants 
present in the IFN gene promoters. Integrating PBM and reporter gene data we 
find that both DNA-binding affinity and affinity-independent mechanisms 
determine the transcriptional activation ability of DNA-bound IRF dimers, 
suggesting that DNA-based allostery plays a role in IRF binding site function. To 
assay the sequence determinants of IRF-dependent transcriptional regulation, 
we propose using a modified massively parallel reporter assay (MPRA). The 
proposed MPRA leverages unique molecular identifiers to improve the accuracy 
of reporter gene quantitation. This work provides new insights into the role and 
limitations of DNA-binding affinity in delineating IRF3/5/7-specific gene 
expression and lays groundwork for further understanding the complexities of 
IRF-dependent transcriptional regulation of innate immune genes. 
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1 CHAPTER ONE - INTRODUCTION 
1.1 The innate immune response 
The innate immune response is an essential component of the mammalian 
immune system that responds rapidly to pathogens. The swiftness of the innate 
immune system depends on the detection of Pathogen Associated Molecular 
Patterns (PAMPs), which are conserved molecular features shared across many 
classes of pathogen (Kumar et al., 2011). Lipopolysaccharide (LPS; present on the 
exterior of many bacteria) and viral genome nucleic acids (ssDNA, dsRNA) are 
PAMPs that elicit strong, pathogen-specific innate-immune responses. Detection 
of these PAMPs is mediated by Pathogen Recognition Receptors (PRRs) present 
on both the exterior and interior of most cell types (Lee and Kim, 2007; Takeuchi 
and Akira, 2010). When a PAMP binds to its corresponding PRR, a rapid signaling 
cascade activates anti-pathogen gene programs necessary for fighting the 
detected pathogen and broadcasting the alarm to surrounding cells (Kawai and 
Akira, 2006). Two well-known PRR families are the Toll-Like receptors (TLRs) and 
the RIG-I-Like receptors (RLR) (Creagh and O’Neill, 2006, 2006; Vogel et al., 
2003). TLRs respond to a broad range of PAMPs associated with both bacteria 
and viruses (Kawai and Akira, 2011; Medzhitov, 2001), while RLRs respond to viral 
nucleic acids (Loo, 2011). 
1.1.1 Innate immune response to viruses 
Viruses infect a wide range of cell types in the human body. After the detection of 
viral PAMPs by PRRs, three key innate immune responses attempt to halt the 
progress of a viral infection: (1) Infected cells up regulate antiviral effectors and 
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may initiate apoptosis to prevent viral compromise of cellular machinery 
(Chattopadhyay et al., 2013; Liu et al., 2013; Zhou et al., 2013); (2) Infected cells 
produce inflammatory cytokines that recruit immune cells to the site of infection 
(Hiscott, 2007; Kimura et al., 2013; Lazear et al., 2015); (3) Activated immune cells, 
like dendritic cells and macrophages, produce interferons and cytokines that 
activate antiviral responses in many cell types and help stimulate the adaptive 
immune response (Barnes et al., 2004; Matta and Barnes, 2019; Tailor et al., 2006; 
Taniguchi et al., 2001). These innate immune functions are coordinated by multiple 
transcription factor (TF) families activated by PRR signaling (Hiscott, 2007).  
1.2 Transcriptional regulation of the innate immune response 
The innate immune system is dependent on complex signaling cascades which 
unfold at the proteomic level; however, an essential endpoint of these mechanisms 
is a change in cell state orchestrated by transcriptional regulation. The activation 
of immune cells in response to pathogens and the production of anti-viral effectors 
is driven by signal dependent TFs in conjunction with cell type-specific TFs 
(Mancino et al., 2015; Medzhitov and Horng, 2009). This integration of 
environment (signal dependent TFs) and cellular context (cell-type-specific TFs) 
allows the human immune system to mount pathogen-specific and immune cell-
type-specific responses (Pope and Medzhitov, 2018). Here we focus on the 
Interferon Regulatory Factors, which play a central role in the innate immune 
response to viruses and bacteria. 
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1.2.1 The Interferon Regulatory Factors (IRFs) 
The Interferon Regulatory Factors (IRFs) were first described approximately 30 
years ago — identified by their ability to bind the Interferon beta promoter (Enoch 
et al., 1986; Miyamoto et al., 1988; Zinn and Maniatis, 1986). The IRFs are named 
for their role in regulating the family of immune signaling peptides known as 
interferons, which coordinate the anti-viral immune response. Since the discovery 
of the first IRF (IRF1), nine human IRFs have been characterized with diverse roles 
in immune regulation and cell development (Table 1.1). The IRFs can be divided 
into two general categories: signal-dependent (IRF1, IRF3, IRF5, IRF7) (Honda, 
Taniguchi, 2006),  and cell-type-dependent IRFs (IRF4, 8) (Tamura et al., 2008) 
— notably excluding IRF2, which is an IRF1-induced repressor (Honda, Taniguchi, 
2006), and IRF6, which is involved in craniofacial development (Ingraham et al., 
2006). 
Despite their diverse functions, all IRFs contain a highly conserved N-terminal 
DNA-binding domain (DBD) that forms a helix-turn-helix structure (Figure 1.1 and 
Figure 1.2). The IRF core binding motif is a short 5’-GAAA-3’ sequence which is 
recognized by contacts along the α3 helix of the IRF DBD which inserts into the 
major groove of DNA (Figure 1.2). The signal-dependent IRF3, IRF5, and IRF7 
bind DNA as dimers and recognize a consensus interferon-stimulated response 
element (ISRE) motif, 5’-GAAANNGAAA-3’. ISREs are found in the promoters of 
key immune genes such as the type-I-interferons (IFNα, IFNβ) (Panne et al., 
2007), type-III-interferons (IFNλ) (Gad et al., 2009; Hillyer et al., 2012; Iversen and 
Paludan, 2010), cytokines (CXCL10) (Brownell et al., 2014), and important antiviral 
effectors (IFIT1-3) (Diamond and Farzan, 2012; Zhou et al., 2013). 
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IRF3, IRF5 and IRF7 (IRF3/5/7) are constitutively expressed at low levels in 
multiple cell types and their signal-dependent activation is an essential part of the 
innate immune response (Honda and Taniguchi, 2006; Tamura et al., 2008). 
Constitutive expression and inducible activation allow IRF3/5/7 to rapidly drive anti-
pathogen gene programs (Chen and Royer, 2010; Honda and Taniguchi, 2006). 
IRF3/5/7 are activated by PRR signaling and bind DNA as phosphorylation induced 
dimers (Chen and Royer, 2010) (Figure 1.3). Dimerization is mediated through a 
C-terminal IRF-association domain (IAD), which is regulated by an auto-inhibitory 
domain (AID) (Chen and Royer, 2010) (Figure 1.3). In the inhibiting state, the AID 
forms a hydrophobic structure that occludes the IAD, preventing dimerization 
(Chen, Royer, 2010). A hinge region in the AID is targeted by PRR-activated 
kinases (TBK1, IKKe, IKKb) (Chen et al., 2008; Marié et al., 2000; Ren et al., 2014; 
Ryzhakov et al., 2015; Takahasi et al., 2010), which phosphorylate serine and 
threonine residues in the hinge, causing the opening of the hydrophobic AID 
(Chen, Royer, 2010) (Figure 1.3). 
Considerable cross-talk between PRR signaling pathways contributes to a robust 
innate immune response (Czerkies et al., 2018; Kawai and Akira, 2011), but can 
make mechanistic interpretations of PRR signaling in stimulated cells challenging. 
Phosphomimetic IRF constructs have been used extensively in the field to study 
IRF dimer-dependent gene regulation and biochemistry (Caillaud et al., 2005; 
Chen et al., 2008; Chen and Royer, 2010; Cheng et al., 2006; Clement et al., 2008; 
Dragan et al., 2007; Foreman et al., 2012; Marié et al., 2000; Mori et al., 2004; 
Prakash and Levy, 2006; Qin et al., 2003) . Serine to aspartic acid (S→D) amino 
acid substitutions in the AID generate constitutively dimeric IRF3/5/7 proteins. We 
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use them throughout the research in this dissertation as an effective molecular tool 
for exploring IRF3/5/7 DNA binding and transcriptional regulation (see chapter 3). 
1.2.2 The interferon regulatory factors 3, 5 and 7 have overlapping yet 
distinct roles 
 IRF3, IRF5 and IRF7 have essential roles in the innate immune response to 
viruses and bacteria. A central output of the IRF-dependent immune response is 
the rapid production of Interferon beta (IFNβ) followed by the expression of IFN 
alpha (IFNα) genes. The secretion of IFNβ by virus-infected cells triggers anti-viral 
responses initiated by IFNβ receptor signaling. The direct role of IRF3 and IRF7 in 
driving IFNβ expression has been extensively studied.  
The canonical model of IFNβ regulation involves the cooperative binding of 
multiple transcription factors (cJun, ATF2, NFκB, IRF3, IRF7) that form an 
‘enhanceosome’ required to initiate transcription in a tightly regulated manner 
(Figure 1.4) (Panne et al., 2007). IRF3 is ubiquitously expressed in most cells and 
is thought to initially drive IFNβ production (Taniguchi and Takaoka, 2001) (Figure 
1.5a). Next, IFNβ receptor signaling up-regulates the expression of IRF7, which 
then continues to drive IFNβ production as an IRF7 homodimer, or IRF3/7 
heterodimer (Figure 1.5b). The level of basal IRF7 expression varies across 
immune cell types and cell environment, which can alter innate immune gene 
expression profiles and the role of IRF3 or IRF7 in IFNβ production. The role of 
IRF5 in IFNβ production is less clear; however, immune cells from IRF3(-)/IRF7(-) 
knock-out mice are still capable of producing IFNβ and this activity is lost in 
IRF3/5/7(-) triple knockout mice (Lazear et al., 2013). Recently, a distinct role of 
IRF5 in driving IFNβ production was shown in human plasmacytoid dendritic cells 
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(pDCs) (Chow et al., 2018). In these cells, IRF5 was found to drive IFNβ 
expression after endosomal TLR signaling, which would allow pDCs to produce 
IFNβ after sampling their environment via endocytosis as part of their surveillance 
role in the immune system. Chow et al. (2018) illustrated the complex and 
overlapping roles of IRF3/5/7 at the same regulatory locus (i.e. IFNβ) that are 
fundamental to understanding IRF-dependent gene regulation. 
Another important set of IRF gene targets are the interferon-alpha family of 
signaling peptides. Humans have 13 IFNα genes, which are differentially regulated 
by IRF3/5/7 (Genin et al., 2009). All IFNα gene promoters feature a conserved 
Viral Response Element (VRE) which contains multiple ISREs or ISRE-like binding 
sites (Figure 1.6). Sequence variations in the IFNα VREs likely contribute to the 
differential regulation of these genes by the IRFs. IRF3/5/7 regulation of the IFNα 
genes is complex, with evidence that IRF3 and IRF7 function as transcriptional 
activators or repressors depending on the relative levels of IRF3/7 expression 
(Genin et al., 2009). IRF5 drives the expression of a subset of IFNα genes (Barnes 
et al., 2001), but has been described as a master regulator of inflammatory 
cytokines (Takaoka et al., 2005). Despite their central role in the response to 
pathogens, little is known about the mechanisms by which IRF3/5/7 target both 
overlapping and distinct gene programs.  
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1.3 Methods for systematically understanding IRF dependent gene 
regulation 
1.3.1 Protein Binding Microarrays (PBMs) 
PBMs are a well-established microarray-based technique to study the in vitro 
binding of proteins to DNA (Berger et al., 2006; Bulyk et al., 1999; Field et al., 2006; 
Linnell et al., 2004; Mukherjee et al., 2004) . PBM experiments involve applying 
protein to a double-stranded DNA microarray and then quantifying the amount of 
DNA-bound protein using a fluorescently labeled antibody (Figure 1.7). Available 
high-density, multi-chambered microarray platforms allow the DNA binding of 
multiple protein samples to be tested in parallel to tens of thousands of DNA 
sequences (Badis et al., 2009; Berger et al., 2008, 2006). This high-throughput 
(HT) platform has facilitated numerous DNA-binding studies on large groups of 
TFs (Badis et al., 2009, 2008; Berger et al., 2008; Franco-Zorrilla et al., 2014; 
Gordân et al., 2011; Grove et al., 2009; Jolma et al., 2013; Wei et al., 2010; Zhu 
et al., 2009) that have provided rich data sets for comparative analysis of TF-DNA-
binding specificity. Furthermore, PBM experiments can be used to measure 
protein–DNA-binding interactions spanning several orders of magnitude in affinity, 
and resolve binding affinities that differ by less than 1.5-fold (Siggers et al., 2011). 
Therefore, comparison of PBM-binding profiles provides a detailed and sensitive 
approach to compare the DNA-binding specificity of TFs. 
PBMs can be used to assay binding to synthetic  (Badis et al., 2009; Berger et al., 
2008, 2006; Linnell et al., 2004; Siggers et al., 2012) or genome-derived (Bolotin 
et al., 2010; Gordân et al., 2013; Mukherjee et al., 2004; Siggers et al., 2011) DNA 
sequences. Studies focused on specific TFs, including those presented in this 
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dissertation, have selected microarray oligos based on prior knowledge about TF 
specificity (Andrilenas et al., 2018; Bolotin et al., 2010; Fang et al., 2012; Udalova 
et al., 2002; Wong et al., 2011) . PBMs using genome-derived DNA sequences 
have also been used to analyze TF specificity and have been instrumental in 
identifying features such as the role of flanking DNA (i.e. genomic context of a 
DNA-binding sites) (Gordân et al., 2013) and coregulatory motifs for multi-protein 
complexes (Siggers et al., 2011). In summary, the PBM is a robust, HT 
methodology that provides a sensitive and flexible platform with which to examine 
TF–DNA-binding specificity. 
1.3.2 Massively Parallel Reporter Assays 
Luciferase reporter assays have been used to study transcriptional regulation 
since the characterization of firefly luciferase in 1985 (Wet et al., 1985). Over the 
past decade, decreases in the cost of high-throughput sequencing (HTS) and DNA 
synthesis have enabled greater use of HTS technologies in biological research 
(Bonetta, 2010; Sboner et al., 2011). Massively parallel reporter assays (MPRAs) 
are a recently developed technique that uses HTS to measure the transcriptional 
activity of many thousands of cis-regulatory elements (CREs) at once (Kwasnieski 
et al., 2012; Melnikov et al., 2012; Tewhey et al., 2016). MPRAs achieve this scale 
by quantitating mRNA abundance transcribed from a complex pool of reporter 
plasmids after transfection into cells. Every CRE present in the MPRA plasmid pool 
is identified by a sequence barcode embedded in the plasmid’s 3’-untranslated 
region (3’-UTR) (Figure 1.8a). This transcribed barcode is a key feature of MPRAs 
and results in reporter mRNAs that identify which CRE induced their expression. 
After mRNA extraction, CRE-associated barcodes are quantified using RNA-seq 
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and normalized to the CRE plasmid abundances (Figure 1.8c). By using high-
throughput sequencing, systematic comparisons of many CREs can be performed 
at a scale that would be prohibitive using low-throughput luciferase assays. 
MPRAs are an excellent experimental paradigm for measuring the relationship 
between TF DNA-binding (PBMs) and transcriptional regulation. The highly-
detailed protein:DNA-binding affinity data generated by PBMs pairs well with 
MPRA experiments. For example, single-nucleotide variation (SNV) alteration of 
transcription factor binding sites, and thus the TF dependent regulation, of gene 
expression is a primary mechanistic model for understanding disease-associated 
expression quantitative trait loci (eQTLs) (Brown et al., 2013; Kasowski et al., 
2010; Majewski and Pastinen, 2011). By integrating PBM-derived TF DNA-binding 
affinities and MPRA data, greater mechanistic insights into human variation may 
be achieved. For example, genome derived and mutational MPRAs have been 
used to functionally assess enhancer sequences and explore the impacts of single-
nucleotide variants on transcriptional regulation (Kwasnieski et al., 2012; 
Patwardhan et al., 2009; van Arensbergen et al., 2019).  
1.4 Thesis rationale 
The innate immune response is an essential component of host defense. Immune 
responses to pathogens are tightly regulated, allowing a robust response to 
pathogens without damaging the host. Defects in innate immune signaling can 
result in chronic bacterial infections and other diseases due to a compromised 
immune response (Ku et al., 2005; van de Vosse et al., 2009), while overactive 
immune responses are a hallmark of autoimmune disease (Ghodke-Puranik and 
Niewold, 2015; Matta and Barnes, 2019). Understanding the regulation of normal 
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immune responses at a mechanistic level may provide insights valuable for human 
health. 
IRF3, IRF5 and IRF7 play a key role in regulating the innate immune response to 
viruses through complex regulatory mechanisms. Considerable progress has been 
made toward understanding the regulation and function of the Interferon 
Regulatory Factors since their discovery 30 years ago (Enoch et al., 1986; 
Miyamoto et al., 1988; Zinn and Maniatis, 1986); however, key questions still 
remain. For example, the molecular determinants of IRF3/5/7’s simultaneously 
overlapping yet distinct gene regulatory activity are still not understood at a 
mechanistic level. 
The research presented in this dissertation makes inroads to understanding how 
IRF3, IRF5 and IRF7 induce both common and factor-specific gene targets. We 
systematically characterize the DNA-binding landscapes of homodimeric IRF3/5/7 
proteins, using PBMs, and examine the impact of small variations in IRF binding 
sites on gene expression (Chapter 3). Additionally, we propose a modified MPRA 
experimental design to elucidate the relationship between IRF DNA-binding affinity 
and transcriptional regulation which leverages massively parallel reporter assays 
(chapter 4). 
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Table 1.1 – The IRFs have diverse roles 
Refer to source paper for table references. Adapted from Tamura et al. (2008) 
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Figure 1.1 – Phylogenetic tree of the Human IRF proteins and their structural domains 
The human IRFs are structurally similar. IRF3, 7, 5, and 6 form an IRF structural 
subfamily. Labels – DNA-binding Domain (DBD), linker (LK), IRF Association 
Domain (IAD), Auto-inhibitory domain (AR). Phosphorylation sites are marked in 
pink. Adapted from Antonczyk et al (2019). (Antonczyk et al., 2019) 
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Figure 1.2 – Structural feature of the IRFs (Composite full-length and DNA Binding Domain) 
A) A composite 3D structure showing the IRF DBD, and C-terminal IRF-
association domain and inhibitory domain (IAD+AID). B) Crystal structure of the 
IRF3 [top] and IRF7 [bottom] DBD interacting with DNA. An alpha helix inserts 
into the major groove to make contacts with DNA. Adapted from De loannes et 
al., 2011 and Shukla et al., 2012. 
(De Ioannes et al., 2011; Shukla et al., 2012) 
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Figure 1.3 – IRF3/5/7 form dimers after activating dimerization 
IRF3/5/7 are activated by phosphorylation. A) Crystal structure of the IRF5 C-
terminal domain (AID+IAD) in an extended, phosphorylated state (yellow – 
phosphates). The phosphorylation opens the hydrophobic helix bundle shown in 
(B). C) Structure showing how the co-activator CBP interfaces with IRF3 without 
an (IAD). D) Structure of the dimerized IRF5 c-terminal domain. Adapted from 
Chen et al. 2010  (Chen and Royer, 2010)  
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Figure 1.4 -  The structure of the interferon beta enhanceosome 
A) Crystal structure model of the IFNβ enhanceosome complex. B) Model of the 
enhanceosome complex interacting with CBP co-activators and transcriptional 
machinery after successful assembly. Adapted from Honda et al., 2006 and 
Panne et al., 2007  (Honda et al., 2006; Panne et al., 2007) 
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Figure 1.5 – Model of the IRF dependent IFN response 
The IRF-dependent anti-viral response is described in two phases: A) The early 
phase is dominantly driven by activated IRF3. IFNβ production in this phase 
activates the late phase via autocrine signaling B) The later phase is driven by 
IRF7 and IRF3/7 heterodimers and drives IRF7 production and the IFNα genes. 
Adapted from Honda and Taniguchi 2006 (Honda and Taniguchi, 2006) 
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Figure 1.6 – The IFNα promoter contain conserved Viral Response Elements (VREs) 
The IFNα Viral Response Elements (VRE) are a conserved cis-regulatory 
module that feature multiple IRF binding sites (B, C, D). Adapted from Civas et 
al. 2006 (Civas et al., 2006) 
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Figure 1.7 – Protein Binding Microarray (PBM) methodology 
Single-stranded DNA oligo arrays (A) are made double-stranded using 
polymerase extension (B) Purified transcription factors tagged with GST are 
applied to the dsDNA PBM (C) After washing excess protein away, bound TFs 
are detected using fluorescently labeled antibodies (D) using a microarray 
scanner. Adapted from Berger et al. 2009  (Berger and Bulyk, 2009) 
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Figure 1.8 – Massively Parallel Reporter Assay (MPRA) methodology 
(A) MPRAs use barcoded mRNA produced from barcode tagged CRE reporters. 
(B) MPRA libraries are synthesized as barcoded oligo pools and are cloned into 
an expression plasmid. (C) To quantify CRE activity, MPRAs use barcode counts 
from sequenced mRNA and normalize them by the plasmid library barcode 
counts. Adapted from White, 2015 (White, 2015) 
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2 CHAPTER TWO - MATERIALS & METHODS 
2.1 Protein Binding Microarray (PBM) methods (Chapter 3) 
 
2.1.1 Molecular Cloning and site-directed mutagenesis 
 
2.1.1.1 Phosphomimetic IRFs 
Constructs used to generate the phosphomimetic IRFs used in this work were 
graciously gifted to us by multiple labs. A constitutively active IRF3-5D 
phosphomimetic plasmid was gifted to us by Dr. Rongtuan Lin. Wild-type IRF5 
plasmids were gifted by Dr. Betsy Barnes and Dr. Nancy Reich. A plasmid 
containing wild-type IRF7 isoform A was also gifted to us by the lab of Dr. Rongtuan 
Lin. All starting IRF3/5/7 constructs were subcloned into the Gateway system 
pDONR221 vector (ThermoFisher).  
Phosphomimetic constructs for IRF5 and IRF7 (IRF5(4D) (Cheng et al., 2006); 
IRF7(8D) (Caillaud et al., 2005)) were made by site-directed mutagenesis using 
the QuikChange Lightning (Agilent) and NEB Q5 (New England Biolabs) site-
directed mutagenesis kits following the manufacturer's instructions. The 
phosphomimetic IRF3(6D) construct (Chen et al., 2008; Lin et al., 1999) was codon 
optimized for E. coli expression and synthesized as an IDT-gBlock (Integrated 
DNA Technologies) with Gateway AttB sites then subsequently cloned into the 
Gateway vector system (ThermoFisher).  
  23 
2.1.1.2 IRF DNA binding Domain Mutants 
Using the phosphomimetic constructs described above, IRF5(K96S) and 
IRF7(S101K) DNA binding domain (DBD) mutations were made with In-vivo 
Assembly (IVA) site-directed mutagenesis (García-Nafría et al., 2016).  
2.1.2 Protein Expression and Purification 
2.1.2.1 IRF3/5/7 protein overexpression using Escherichia coli 
Interferon regulatory factor phosphomimetic proteins were overexpressed using E. 
coli. Expression conditions were optimized on a per-protein basis to produce the 
greatest quantity of full-length protein and minimize truncated protein products as 
indicated by anti-GST western blot. 
GST-IRF5(4D) (pDEST15) and GST-IRF7(8D) (pDEST15) were expressed using 
the OverExpress C41(DE3) E. coli strain (Lucigen) co-transformed with the pRare 
tRNA plasmid (Novagen). Transformed bacteria were propagated on Terrific Broth 
(TB) + 1% glucose + antibiotic plates. Protein expression was carried out in TB + 
1% glucose + antibiotic with an initial outgrowth at 37°C up to OD 0.6 followed by 
0.5 mM IPTG induction and expression at room temperature (~20°C) for 5 h. 
Addition of glucose to media (to suppress leaky protein expression) and co-
transformation with pRare plasmid (to enhance translation) led to the highest yield 
of full-length protein.  
Codon optimized GST-IRF3(6D)-6xHis(pDEST15) protein was expressed using 
BL21(DE3) E. coli co-transformed with the pLysS plasmid. Transformed bacteria 
were propagated on TB + antibiotic plates and protein expression was carried out 
in TB + antibiotic media with an initial outgrowth at 37°C up to an O/D of 0.6 
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followed by 0.2 mM IPTG induction and expression at room temperature for 5 h. 
Bacterial cultures were pelleted and stored at -80°C until lysis and purification. 
2.1.2.2 FPLC affinity chromatography purification 
IRF5 and IRF7 were purified with Glutathione-S-Transferase (GST) affinity 
chromatography using GSTrapFF columns (GE Healthcare) and an ÄKTApurifier-
10 Fast Protein Liquid Chromatography (FPLC) device (GE Healthcare). The 
binding and elution buffers recommended in the GSTrapFF manual were used and 
supplemented with 1 mM PMSF serine protease inhibitor (Binding: PBS, pH 7.3 
[140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3] + 1 mM 
PMSF; Elution: 50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0 + 1 mM 
PMSF). Sample was buffer exchanged into binding buffer + 20% glycerol using 
Amicon 30k MWCO filtration spin units (EMD-Millipore) then snap frozen and 
stored at -80°C. Protein concentration was determined using the Coomassie Plus 
Bradford assay (Pierce).  
IRF3 was tandem affinity purified first using immobilized metal ion affinity 
chromatography (IMAC) (C-terminal-6xHis tag) followed by GST affinity 
chromatography (N-term-GST tag). Frozen cell pellets were resuspended in IMAC 
binding buffer supplemented with protease inhibitors (Sigma P8340), powdered 
lysozyme and Benzonase endonuclease (EMD Millipore). The resuspension was 
then lysed using an EmulsiFlex-C3 (Avestin, Inc.) homogenizer that was prechilled 
using recirculated ice-cold binding buffer. Multiple passes and a large buffer 
volume (100 - 200 ml) were required to reduce sample viscosity enough to allow 
thorough lysis by the EmulsiFlex-C3 and subsequent loading onto the 
chromatography columns. Lysed samples were clarified by centrifugation at 4°C 
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at 15,000 RCF for 60 min and the supernatant was filtered using a 0.45 μm PES 
syringe filter (Fisher Scientific) before loading into the ÄKTApurifier-10 FPLC. 
HIS purification was carried out using HisTrapFF columns (GE Healthcare) and 
the buffer conditions recommended by the manufacturer. (Binding buffer: 20 mM 
sodium phosphate, 500 mM NaCl, 20 mM imidazole, pH 7.4; Elution buffer: 20 mM 
sodium phosphate, 500 mM NaCl, 500 mM imidazole, pH 7.4) Buffers were 
supplemented with 1mM PMSF serine protease inhibitor. To prepare samples for 
affinity chromatography and prevent precipitation of IMAC purification eluates, 
samples were slowly buffer exchanged using Slide-a-Lyzer 3.5K MWCO dialysis 
cassettes (Thermo Scientific). Dialysis was carried out at 4°C first using IMAC 
binding buffer to slowly reduce the imidazole concentration of the sample. The 
sample was then dialyzed with GST-binding buffer overnight using a flow regulated 
beaker system allowing for the dropwise addition of target buffer over many hours. 
The next day the GST-binding buffer was refreshed and dialysis continued while 
preparing for GST affinity chromatography. The sample was then diluted in freshly 
made GST-binding buffer for automated FPLC sample loading. GST-tag 
purification was carried out as described for IRF5 and IRF7. 
IRF5(K96S) and IRF7(S101K) DNA binding domain (DBD) mutations were made 
with In-vivo Assembly (IVA) site-directed mutagenesis (García-Nafría et al., 2016). 
IRF-DBD mutant proteins were expressed and purified as described above. 
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2.1.3 Protein Binding Microarrays (PBM) 
2.1.3.1 PBM Design 
Our IRF-specific PBM design included both synthetic and genome-derived IRF 
binding sites. Synthetic probes: Microarray probes with synthetic sites were based 
on 108 seed IRF binding sites that were each 20-bp long (for 2-bp half-site 
spacers), and 54 seed sites that were 21-bp (for 3-bp half-site spacer). Seed IRF 
sequences were within constant flanking DNA sequence (Figure 1A). For each 
seed sequence, we included all single-nucleotide variants (SNVs) across the 20-
bp or 21-bp long site, for a total collection of 10,044 synthetic IRF sites. For each 
unique IRF site, 6 replicate probes were included in each orientation (12 replicates 
per unique site). The 162 seed sequences were chosen based on IRF binding sites 
from the literature, available HT-SELEX datasets (Jolma et al., 2013), and 
preliminary PBM experiments. Seed sequences were selected to capture a range 
of binding affinity, and to include alternate core sequences (i.e., alternates to the 
canonical 5’-GAAA-3’ core). This seed+SNV design allows us to directly compare 
IRF-specific DNA binding preferences across the IRF-binding sites in a 
straightforward manner, and to generate position weight matrices (PWMs) with 
relatively small number of sequences (see below).  
Genome-derived probes: Putative IRF binding sites from the promoters of type I 
IFN genes, and from published cis-regulatory elements for other genes (e.g., 
CXCL10) were extracted from the genomes as 21-bp genomic fragments and 
centered on the microarray probes in an identical manner to the synthetic probes. 
The proximal promoters of the type-1 interferons and other cytokines were 
scanned using BioPython (v1.68; bio.motifs, bio.SeqUtils.lcc modules; (Cock et al., 
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2009; Mangalam, 2002)) and degenerate IRF consensus motifs with a 2-bp or 3-
bp spacer length (figure 2.1). Sequences with a low stringency PWM score above 
zero and a sequence complexity score above 0.5 were included in the array. These 
selection criteria were empirically selected to remove long poly-A runs present in 
the IFN promoters while still capturing potential IRF binding sites. To reduce 
redundant genomic probes, sites within 1 bp of each other were removed retaining 
probes with the PWM hit closest to the end of the PBM probe. To control for 
potential IRF binding site shifts, trimmed probes were generated by replacing the 
flanking regions of the IRF-PWM with a low/moderate affinity constant sequence 
as determined in preliminary array designs. Genomic loci and full PBM probe sets 
are available upon request and published online (Andrilenas et al., 2018) 
https://doi.org/10.1093/nar/gky002. 
2.1.3.2 PBM Experiments 
PBM experiments were performed using custom-designed microarrays (Agilent 
Technologies Inc. AMADID 084215, 4x180K format). Microarrays were double-
stranded as previously described (Berger et al., 2006; Berger and Bulyk, 2009). 
Wash steps were carried out in coplin jars on an orbital shaker at 125 rpm. Double 
stranded microarrays were first pre-wetted in PBS containing 0.01% Triton X-100 
for five min, rinsed in a PBS bath, and then blocked with 2% milk in PBS for 1 hour. 
Following the blocking step, arrays were washed in PBS containing 0.1% Tween-
20 for 5 min, then in PBS containing 0.01% Triton X-100 for 2 min and finally briefly 
rinsed in a PBS bath. Arrays were then incubated with the protein sample(s) for 
one hour in a binding reaction containing: 2% milk with 10 mM Tris, pH 7.5; 50 mM 
NaCl; 2 mM DTT; 0.2 mg/ml BSA; 0.02% Triton X-100; and 0.4 mg/ml salmon 
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testes DNA (Sigma D7656). See Table 2.1 for PBM protein concentrations and 
conditions. After protein incubation, microarrays were washed with PBS containing 
0.5% Tween-20 for 3 min, then in PBS containing 0.01% Triton X-100 for 2 min 
followed by a brief PBS rinse. Microarrays were then incubated with 20 μg/ml of 
Alexa Fluor-488 conjugated Anti-GST antibody (LifeTech, Cat# A-11131) in 2% 
milk in PBS for 20 min. Excess antibody was removed by washing with PBS 
containing 0.05% Tween-20 for 3 min, then PBS for 2 min. 
2.1.3.3 PBM data acquisition and analysis 
Microarrays were scanned with a GenePix 4400A scanner and fluorescence was 
quantified using GenePix Pro 7.2. Exported data were normalized using 
MicroArray LINEar Regression (Berger et al., 2006). Microarray probe sequences 
and fluorescence values from each experiment are available upon request and 
published online (Andrilenas et al, 2018). IRF dimers exhibit an orientation-specific 
bias in our PBM experiments; therefore, data from probes in a single orientation 
(i.e., ‘_o2’ probes; available upon request and online 
https://doi.org/10.1093/nar/gky002 (Andrilenas et al., 2018)) was used in our final 
analysis. However, all results were observed for probes in both orientations.  
PBM experiments for the IRF3/5/7 phosphomimetic dimers were performed at four 
protein concentrations for each IRF dimer (Table 2.1). A saturation-binding curve 
was fit independently to the fluorescence values for each probe sequence: 
 𝐹 =	𝐹$%& ∗ [𝑃]𝐾, + [𝑃]  
 
(2.1) 
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F is probe fluorescence, Fmax is max fluorescence, [P] is applied protein 
concentration, Kd is dissociation constant. We previously showed that this 
approach can accurately estimate relative binding affinities over a wide affinity 
range (Siggers et al., 2011). Curve fitting was performed in the statistical package 
R using the optim function (method - “Brent”, Fmax – highest fluorescence value on 
PBM at highest protein concentration) with the cost function:  
 𝐶𝑜𝑠𝑡 = 	2⎝⎛1 −
𝑙𝑜𝑔 9𝐹$%& ∗ [𝑃]:[𝑃]: + 𝐾𝑑:<𝑙𝑜𝑔=𝐹>?@: A ⎠⎞
DE
:FG 						 
 
(2.2) 
Kd values were determined for each PBM probe, the median Kd across the six 
replicate probes was then reported for each unique DNA sequence on the PBM. 
We refer to these resulting binding constants as KPBM to highlight that these are 
PBM-derived estimates of relative binding constants. KPBM values were virtually 
identical (Pearson correlation R = 0.98) when a single value was determined by 
fitting simultaneously on fluorescence measurements from all replicate probes 
(i.e., 4x6=24 fluorescence values). Mutant IRF experiments were performed at a 
single concentration (Table 2.1). For each DNA sequence, the median 
fluorescence intensity, over 6 replicate probe measurements, is used to quantify 
the binding of the protein to the DNA. We found that KPBM values determined from 
PBMs done at multiple concentrations (as described above) was approximated 
well by PBM experiments performed at a concentration ~100-200 nM. For all PBM 
experiments, z-scores were determined for the log(F) or log(KPBM) values using the 
mean (μ) and variance (σ2) of the values for the randomly selected background 
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probes: zi = (log(Fi) - μ)/σ. Z-scores provide an internally consistent way to quantify 
the specificity above background for measurements in each experiment.  
2.1.3.4 SNV method for constructing position frequency matrices (PFMs) 
PFMs can be constructed using the PBM z-score values of a single seed sequence 
(i.e., starting sequence), and the 3x21 associated SNV sequences. In the low-
protein limit (i.e., when [P] << Kd), z-scores are related to log(F) ~ log(Kd ) ~ E, 
where E is the binding free energy. Therefore, starting from an individual seed 
sequence, we compute the relative base preferences for base k at position i as a 
probability based on the Boltzmann distribution: 
 𝑃:H = 𝑒JKLM∑ 𝑒JKLMOHFG  (2.3) 
Zik – z-score for this particular seed sequence with SNV k at position i. β - a 
normalization factor chosen to maximize the correlation between the PFM scores 
and the PBM-measured log(KPBM) values. We found that β=1 worked well for all 
our experiments. Using this approach, we can generate a PWM from a single seed 
and its complement of SNV probes. To generate a representative PFM for a PBM 
experiment we determine individual PFMs using the 15 top-scoring seed 
sequences and average the fifteen individual pik values to determine an average 
PFM for the experiment. Logos were then generated using the ENOLOGOS 
webserver (Workman et al., 2005), with background frequencies set to equally 
probable. To identify base positions that are discriminatory for a single dimer, we 
systematically analyze our PBM data to find single-base changes that abrogate 
binding of one IRF dimer but not another. Specifically, to identify base positions 
that discriminate between two dimers, we analyze the binding to all pairs of DNA 
sequences that differ by a single base (i.e., SNV pairs). SNV pairs are identified 
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where one IRF dimer is bound with high-affinity to both sequences (z-score > 8.0 
for both probes, and z-score difference between probes < 3.0) while the other IRF 
dimer is bound with high-affinity to one probe (z-score 8.0) but with low affinity to 
the other probe (z-score < 5.0, and z-score difference between probes > 5.0). 
Identifying all such SNVs reveals base positions and variants that provide strong 
discrimination between IRF dimers. 
2.1.4 Electro-mobility shift assays (EMSAs) 
2.1.4.1 EMSA probe generation 
IRF binding mode EMSAs (Chapter 3 - Figure 3.5C) used complementary oligo 
annealing to form double-stranded EMSA probes. Briefly, single stranded DNA 
oligos were annealed at 100 µM concentration in TE buffer + 50 mM NaCl (10mM 
Tris, 1mM EDTA, 50mM NaCl, pH 8.0). Probes were denatured at 95°C for 2 min 
in a dry-heating block which was allowed to cool to room temperature. See Table 
2.2 for EMSA oligo sequences. 
IRF PBM probe EMSAs (Chapter 3 - Figure 3.3) used oligo extension to generate 
60-bp dsDNA probes. Briefly, probes were double-stranded using BST polymerase 
(New England Biolabs). Probe and primer were slowly annealed from 95°C to 63°C 
using a thermocycler with a 0.1°C/sec cooling rate in buffer containing 8 µM probe 
ssDNA oligo, 8 µM extension primer, 1x ThermoPol buffer (New England Biolabs), 
1.6 mM dNTPs (New England Biolabs). Four units of BST polymerase diluted in 
1x ThermoPol buffer were pre-heated to 63°C and quickly added to the annealed 
mixture. The isothermal double stranding reaction was held at 63°C for 1.5 h, then 
double-stranded probes were purified using a MinElute PCR purification kit 
according to manufacturer's instructions (Qiagen).  
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2.1.4.2 DNA probe radiolabeling 
Purified dsDNA probes were radiolabeled with [γ-32P]-adenosine triphosphate 
(PerkinElmer) using T4 Polynucleotide Kinase (New England Biolabs) following 
manufacturer’s protocol. Radiolabeled probes were purified using a QIAquick 
nucleotide removal kit (Qiagen) according to the manufacturer’s instructions. 
Radiolabeling and purification yield were assumed to be 100 percent efficient for 
EMSA probe concentration calculations.  
2.1.4.3 EMSA binding reactions, electrophoresis and imaging 
Experiments were carried out as described (Hellman, Fried, 2007). Binding 
reactions were carried out in 20 µl volumes containing: 1 nM P-32 labeled DNA 
probe and PBM buffer with nonspecific DNA competitor (10 mM Tris pH 7.5; 50 
mM NaCl; 2 mM DTT; 0.08% Triton-X100; 50 ng/µl poly(dI:dC) (LI-COR 
Biosciences); 0.005 ug/µl salmon sperm DNA (LI-COR Biosciences)). To prevent 
adsorption to tubes and pipette tips, protein samples were diluted to appropriate 
concentrations in reaction buffer + 1 mg/ml BSA (New England Biolabs). Reactions 
were incubated at room temperature for 45 min. Before loading into gels, 1 µl of 
50% glycerol and 1 µl Orange Loading Dye were added to each reaction (LI-COR 
Biosciences). Reactions were resolved in 6% polyacrylamide gels (29∶1 cross-
linking) with 0.5x TBE running buffer at 10 V/cm in a 4°C water bath until the 
loading dye front reached the bottom of the gel (~2 - 3 h depending on gel length). 
Before drying under vacuum, EMSA gels were fixed for 30 min using a 20% 
Methanol, 10% acetic acid solution then rinsed in ddH2O for 15 min and 
transferred to Whatman filter paper. Autoradiography was performed using a BAS 
storage phosphor screen (GE Healthcare). After overnight exposure, the phosphor 
screen was scanned using a Typhoon-Trio scanner (GE Healthcare). Typhoon 
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square root space .GEL files were linearized using the ImageJ Linearize GelData 
plugin. To improve band visibility, the brightness of the linearized TIFF files was 
decreased by 25 units using Adobe Photoshop CS6. 
 
2.1.5 Reporter Assays 
IRF3(6D), IRF5(4D) and IRF7(8D) were cloned into the N-terminal His-tagged 
protein mammalian expression plasmids (pDest26) (LifeTech). HEK293T cells 
were cultured in DMEM (Gibco 11965092) + 10% FBS (Gibco 26140079). Cells 
were plated in tissue culture treated 96-well plates seeded at 12 000 cells per well 
and allowed to adhere overnight. PEI:DNA complexation reactions were carried 
out in 500 µl of serum free media and cells were transfected using 
polyethylenimine (PEI) (Polysciences, Inc.) at a ratio of 2:1 (PEI:DNA). Each 96-
well plate well received 10 µl of transfection mixture containing: 12.5 ng of Tk-
Luciferase transfection normalization plasmid (pGL4.54); 10 ng of E1α-eGFP 
carrier DNA; 12.5 ng of reporter plasmid (pNL3.1); and 1.25 ng of His-tagged 
protein expression plasmid (pDest26) or GFP plasmid (E1α-eGFP) in background-
expression controls. The key difference between an experimental condition and a 
GFP control condition, is whether a phosphomimetic IRF is being over expressed 
versus GFP. Every IRF-binding site reporter plasmid (pNL3.1: i3, i5, i7, C-2, C-3, 
i7-2, empty) was tested with exogenous protein expression (IRF3, IRF5, IRF7, 
GFP), with the GFP conditions as controls. Additionally, every well received the 
luciferase transfection control plasmid (pGL4.54). Cells were incubated with 
transfection reagent overnight and then cell culture media was changed. Cells 
were lysed and assayed 24 h after transfection using the Nano-Glo Dual Luciferase 
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reporter assay system (Promega). Dual-luciferase signal was quantified using a 
VICTOR-3 plate reader (PerkinElmer). Reporter assay conditions had at least 
three biological replicates and at least three technical replicates per biological 
replicate 
2.1.5.1 Normalization of reporter assay data 
Nano Luciferase reporter plasmid signal was normalized to the constitutive 
luciferase signal (i.e. signal from pGL4.54 plasmid, transfection normalization) for 
each transfected well: 
For each well: 𝑁𝑜𝑟𝑚: = 𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙	𝑅𝑒𝑝𝑜𝑟𝑡𝑒𝑟:	[𝑁𝑎𝑛𝑜𝐿𝑢𝑐, 𝑝𝑁𝐿3.1]𝐶𝑜𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑖𝑣𝑒	𝑡𝑟𝑎𝑛𝑠𝑓𝑒𝑐𝑡𝑖𝑜𝑛	𝑐𝑜𝑛𝑡𝑟𝑜𝑙:	[𝐿𝑢𝑐, 𝑝𝐺𝐿4.54]  
Where 𝑁𝑜𝑟𝑚:	is the transfection normalized value for a given well. 
Fold-induction values for each Protein X Reporter combination were calculated 
relative to the background-expression signal for each reporter plasmid condition: 
For each condition well: 𝑔𝑓𝑝_𝑛𝑜𝑟𝑚: = 𝑁𝑜𝑟𝑚:[𝑅𝑒𝑝𝑜𝑟𝑡𝑒𝑟	𝑋	𝐼𝑅𝐹]𝑚𝑒𝑎𝑛(𝑁𝑜𝑟𝑚:→&[𝑅𝑒𝑝𝑜𝑟𝑡𝑒𝑟	𝑋	𝐺𝐹𝑃])  
Where 𝑁𝑜𝑟𝑚:→&  represents the transfection normalized data from all biological 
and technical replicates for a given Reporter x GFP condition. 
Descriptive statistics (mean, standard deviation, etc.) and plots of all intermediate 
steps for all experimental conditions are provided in Chapter 3: luciferase (Figure 
3.10; Table 3.1), nano luciferase (Figure 3.11, Table 3.2), transfection normalized 
(Norm; Figure 3.12, Table 3.3), GFP normalized (gfp_norm; Figure 3.13, Table 
3.4).  
  35 
We chose to normalize reporter assay data to the GFP condition that has no IRF 
over expression to account for potential variation in background activity of the 
reporter plasmids. We also used GFP over expression to account for the impact of 
transcriptional and translational burden incurred by cells over expressing the 
IRF3/5/7 constructs. When examining the raw transfection normalized data, we 
find that our data still suggests affinity independent transcriptional regulation by 
IRF3/5/7. 
Computations were performed using the Python programming language and the 
Pandas module (see below). Bar plots of reporter assay data in Chapter 3 (Figure 
3.9) are scaled to the i7-2 reporter for each protein condition.  Scaling to the i7-2 
reporter values was an aesthetic choice that allowed for the use of a single set of 
axes while not altering the relative relationships between data points in a given 
protein condition. All intermediate plots and data are in Chapter 3 (Figures 3.10 – 
3.14; Table 3.1 – 3.5)  
Stepping through the normalization process: 
1. Transfection Normalization: Divide each nano-luciferase data point by its 
corresponding luciferase transfection control. (Norm) 
2. GFP Normalization: For each transfection normalized Norm data point, 
divide each Norm value by the mean of the corresponding Norm[reporter x 
GFP]  data. (gfp_norm)  
3. I7-2 reporter scaling: Divide the GFP normalized values (gfp_norm) by the 
mean of the I7-2 data for a given protein condition. 
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Python Code: 
## %% Setup ## 
import pandas as pd 
 
## %% Data Import ## 
data_file = 'reporter_data_export_sep23.csv' 
df = pd.read_csv(data_file) 
 
## %% Normalize ## 
# Divide each nanoluc value by its luciferase value 
df['norm'] = df['nanoluc'] / df['luc'] 
 
 
# Group data by experiment date, then reporter condition. 
Divide each 'norm' data point 
# by the mean of the GFP control for that respective date 
and reporter condition. 
df['gfp_norm'] = df.groupby(['Date', 'Reporter']).apply( 
    lambda x: x[['norm']] / x.loc[x['Protein'] == 'GFP', 
['norm']].mean()) 
 
## %% Scale Data ## 
# Group data by protein. Divide gfp_norm values from each 
protein group  
# by the mean of the respective i7-2 gfp_norm values 
df['i72_scale'] = df.groupby(['Protein']).apply( 
    lambda x: x[['gfp_norm']] / x.loc[x['Reporter'] == 'i7-
2', ['gfp_norm']].mean()) 
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2.1.6 Western Blots 
2.1.6.1 Phosphomimetic IRF overexpression western blots 
IRF overexpression conditions from reporter assays were scaled up to generate 
whole cell lysates from 10cm culture plates. Plates were PEI transfected as 
described above with 7.2 µg of plasmid DNA consisting of: pGL4.54 TK-Luciferase 
[2.48 µg]; E1α-eGFP [1.99 µg]; pDEST26 IRF3/5/7 or additional E1α-eGFP [0.25 
µg]; pGEM3zf(-) carrier DNA [2.48 µg], these quantities are scaled up from 96-well 
plates assuming a 20 µg typical 10cm plate transfection. Carrier DNA was used in 
place of any IRF-specific pNL3.1 NanoLuc reporter plasmids to avoid the effect of 
differential transcriptional output from the reporter plasmids. Cells were harvested 
24-h after transfection and lysed on ice in RIPA buffer + 1:100 protease inhibitor 
cocktail (50 mM Tris HCl, pH 8.0; 150 mM NaCl; 1% Tergitol (NP-40); 0.5% sodium 
deoxycholate; 0.1% SDS; Sigma P8340). Released genomic DNA was digested 
with 0.5 µL Benzonase nuclease (Sigma E1014). Total protein content was 
measured using the Coomassie Plus (Bradford) Assay kit (Pierce) with assay 
compatible dilutions of RIPA buffer in BSA standards (1:50) and samples. SDS-
polyacrylamide gels were run with 30 µg of total protein per lane as well as 25 ng 
of purified GST tagged IRF protein as a positive control. Electrophoresed protein 
was then transferred to Immobilon-FL PVDF membranes (Millipore-Sigma). 
Membranes were blocked in Tris Buffered Saline + 1% Tween-20 (TBST; 20 mM 
Tris, 150 mM NaCl) with 5% w/v non-fat milk. Primary antibodies were incubated 
with membranes overnight at 4°C in TBST without milk at the following dilutions: 
1:5,000 mouse-anti-IRF-3 (Santa Cruz Bio, sc-33641); 1:5,000 mouse-anti-IRF-5 
(Santa Cruz Bio., sc-390364); 1:4,000 mouse-anti-IRF7 (Santa Cruz Bio., sc-
74472); 1:5,000 rabbit-anti-PARP1 (Santa Cruz Bio., sc-7150). Membranes were 
washed four times in TBST and incubated with 1:10,000 fluorescent secondary 
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antibodies in TBST+5% milk for one hour (Invitrogen AlexaFluor 488-goat-anti-
mouse, A11001; LifeTech. Cy5-goat-anti-rabbit, A10523). Membranes were 
washed again and imaged on a Typhoon Trio imager (GE Healthcare). Dual-color 
composite images were created from linearized GEL files (see EMSA methods 
above) and brightness and contrast were adjusted to increase signal-to-
background ratio in ImageJ.  
2.2 MPRA Methods 
Massively Parallel Reporter Assay experimental design and procedures were 
based on a protocol and personal communications with the lab of Dr. Barack 
Cohen at Washington University in St. Louis, Missouri. 
2.2.1.1 MPRA Library design 
A complex oligo pool was ordered from Agilent. 15,000 sequences were custom 
ordered with sequences divided amongst three MPRA library experiments. The 
Interferon Regulatory Factor MPRA library consists of 6,131 unique barcodes with 
10 barcodes per regulatory element. Ten barcodes were considered sufficient for 
cells with transfection efficiencies of 10 - 40% (personal communications with 
Cohen lab).  
The IRF MPRA library was designed to include multiple experiments derived from 
IRF PBM data. IRF MPRA regulatory elements were designed using the type-I 
interferon Viral Response Element structure (VRE) where two IRF dimer sites are 
adjacent to each other with a short spacer (See Chapter 4 - for more information 
on experimental features). Redundant regulatory elements were removed before 
barcode assignment to reduce the sequence space required by the library. MPRA 
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cloning features were designed in coordination with Jessica Keenan and Ashley 
Penvose. 
2.2.1.2 MPRA vector engineering 
MPRA libraries were cloned into a modified pNL3.1 (Promega) vector, hereafter 
referred to as pNL-MPRA. The pNL3.1 vector was modified for use with a 
GoldenGate cloning strategy that utilizes two Type-IIs restriction enzymes 
frequently used in complex GoldenGate assembly: BsaI and BbsI (Andreou and 
Nakayama, 2018; Engler and Marillonnet, 2013). The ccdB and CamR cassette 
from the Gateway cloning vector pDEST26 was added to the pNL3.1 vector to 
reduce background colonies that lack the MPRA library insert. The vector 
modification process required mutating BsaI and BbsI sites present in the pNL3.1 
vector backbone and ccdB gene. Creating the pNL-MPRA vector also involved 
removing the NanoLuc gene and minimal promoter and adapting the multicloning 
site to use BsaI sites for library insertion. The IRF-MPRA design uses alternative 
restriction sites (Acc65I and XbaI) in place of the BsaI sites given the similarity of 
the BsaI site (NNNN|NGAGACC) to an alternate IRF binding site present in the 
MPRA oligo pool (GAGACCGAGA).  
2.2.1.3 MPRA molecular cloning 
To prepare for MPRA library cloning, pNL-MPRA-ccdB vector was digested with 
the restriction enzymes Acc65I and XbaI (New England Bio) using NEB 3.1 
restriction buffer which allowed for the highest activity of both enzymes (Acc65I: 
100%; XbaI 75%). Vector DNA was simultaneously dephosphorylated using 
recombinant Shrimp Alkaline Phosphatase (rSAP; New England Bio) to prevent 
re-ligation of the vector. Digests were purified using a PCR purification column 
(Epoch Life Science). 
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The 10 pmol Agilent OLS ssDNA library was resuspended in 100 µl of nuclease 
free TE buffer pH 8.0 (Invitrogen) at an end concentration of 0.1µM. The IRF-
MPRA library was amplified from the total Agilent OLS pool using IRF-MPRA 
specific primers in a low cycle PCR reaction (Table 2.3A) using primers in Table 
2.4. Library PCRs resulted in poor DNA yield after PCR DNA cleanup and multiple 
reactions were pooled and purified to reach sufficient DNA concentration for 
downstream handling. Purified dsDNA MPRA library was digested using the 
restriction enzymes Acc65I and XbaI and then enzymes were heat inactivated for 
20min at 65°C. Small scale regulatory element insert ligations were performed 
using unpurified restriction reaction and purified phosphatase treated vector. Molar 
ratios from 1:3 to 1:5 (Vector:Insert) were tested in small 20µl ligations. Ligation 
reactions were performed using T4 DNA ligase in NEB CutSmart buffer 
supplemented with 1mM ATP (New England Bio) and incubated for 1 hour at 16°C 
and then 10 min at 23°C followed by heat inactivation at 65°C for 20 min. Small 
scale E. coli transformations were performed using 10µl of NEB DH5ɑ chemically 
competent cells with 2µl of ligation reaction. Transformation reactions were 
suspended in 100µl of SOC media and shaken at 37°C for 15min and then 100µl 
was plated on Nunc OmniTray (ThermoFisher) microplate format agar plates with 
carbenicillin. Colony counts were estimated using the OpenCFU (v3.9.0 for 
Windows) software and plate images acquired using an Epson flatbed scanner 
(Geissmann, 2013). The Epson scanner was used because of its front illumination 
imaging sensor. A ligation vector:insert molar ratio of 1:4 had the greatest colony 
count per plate.  
The number of colonies required to be 99% confident that all sequences in the 
IRF-MPRA library were captured was estimated using the geometric distribution 
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in equation 2.4, where 𝑝 is the probability of picking a single oligo from the IRF-
MPRA pool, assuming a 50% error rate from Agilent, and 𝑛 is the number of 
colonies to collect (eq. 2.4).  
 
 𝑃(𝑝𝑖𝑐𝑘𝑖𝑛𝑔	𝑎𝑙𝑙	𝑐𝑜𝑟𝑟𝑒𝑐𝑡	𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠) = 1 − (1 − 𝑝)(lmG) 
 (2.4) 
 𝑝 = 1 (2 ∗ 𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑏𝑎𝑟𝑐𝑜𝑑𝑒𝑠	𝑖𝑛	𝑙𝑖𝑏𝑟𝑎𝑟𝑦)q  (2.5) 
Equation 2.4 can then be rearranged to solve for the number of colonies needed 
to have a 99% probability that all barcodes are represented in the culture: 
 
 𝑁𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠	 = 	𝑙𝑜𝑔(1 − 	0.99)𝑙𝑜𝑔(1 − 𝑝) 	− 	1 (2.6) 
For the IRF-MPRA library with 3,161 unique barcodes we must select at least 
29,110 colonies to have a 99% probability that all barcodes are represented in the 
library. At a colony count of 2,000 colonies per plate, approximately 15 plates will 
be required to have sufficient colony counts. 
Ligation and transformation reactions were scaled up to multiple 50µl 
transformations using the estimated colony counts found during ligation tests. A 
vector only, no insert control reaction was also performed. Transformations were 
performed with a 30 min. Incubation on ice followed by a thermocycler 
transformation program (Pre-chill at 4°C; 30 sec at 42°C; return to 4°C; then move 
to ice for 5 min). 500 µl of 37°C SOC media was added to each 50 µl reaction and 
cultures were shaken for 15 min at 37°C, after recovery, 100 µl of culture was 
spread across each OmniTray plate with a bar spreader. Plates were incubated at 
37°C for 12 - 18 h. Four randomly selected plates were counted as described 
above, using OpenCFU, to estimate colony counts. Colonies were scraped from 
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plates using an extra-large metal dry-reagent spatula (Fisher Scientific 14-373-25). 
This tool was used as opposed to a plastic cell scraper or glass slide, as it could 
be flamed between plates and easily manipulated with gloved hands. Scraped 
colonies were resuspended in a small number of 50 ml conical tubes, each 
containing 15 mL of Luria Broth (LB). Colony suspensions were pooled in a 2 L 
baffled flask and additional media was added to bring the final culture volume to 
20 ml of LB per plate. An appropriate volume of 1000x carbenicillin antibiotic was 
added to the large culture as well as 5 µl of Antifoam 204 (Sigma Aldrich). Initial 
small-scale pilot liquid cultures at 37°C did not produce turbid cultures after 24 h. 
We found that reducing the culture temperature to 30°C resulted in expected 
growth. The MPRA library culture was shaken at 250 RPM at 30°C for 5 h. The 
culture optical density at 595 nm reached approximately 1.3 units. The cell culture 
was then pelleted in 50 ml conical tubes at ~1500 RCF for 15 min and frozen at -
80°C. Plasmid DNA from the large-scale MPRA-library cell pellets was isolated 
using a Plasmid Plus Maxi Kit (Qiagen) following the manufacturer’s high-yield 
purification protocol. Qiagen only recommends a maximum of 100 ml of overnight 
culture, given the decreased culture time and culture temperature, a pellet from 
400 ml of media did not overload the column. 
2.2.1.4 MPRA library cloning quality assurance 
MPRA library step 1 was sequenced for quality assurance using the 
Massachusetts General Hospital Center for Computational & Integrative Biology 
DNA core (MGH CCIB) CRISPR amplicon sequencing service. A 200 bp amplicon 
was generated for sequencing using PCR with primers flanking the MPRA library 
insert (see primers in Table 2.3). Sequencing data was analyzed using custom 
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python scripts (Python version 3.5, Biopython 1.73, Pandas 0.24.2), as well as 
BWA (Li, Durbin, 2010) and BBtools(Bushnell et al., 2017)  
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Figure 2.1- Degenerate Position Frequency Matrices. 
Degenerate Position Frequency Matrices used to extract potential IRF3/5/7 sites from the human 
type-1 interferon promoters for inclusion in the IRF protein binding microarray design. PFMs are a 
count-based model of DNA sequence motifs; here, each PFM has been visualized as a sequence 
logo. The 2-bp PFM (top) has a two base pair spacer between the core IRF GAAA sites, the 3bp 
(bottom) has a 3 base pair spacer.  
 
  
  45 
Table 2.1 - Protein Binding Microarray experimental conditions used in PBM experiments. 
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Table 2.2 - Single stranded DNA oligos used to generate EMSA probes. 
The IRF binding mode EMSAs used complementary oligo annealing to generate double-stranded 
probes. The complementary sequences are not listed. The IRF PBM Probe EMSAs used 
polymerase extension to form dsDNA products. The annealing site for the complementary 
extension primer is underlined. Refer to Chapter 3, Figure  
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Table 2.3 – MPRA Protocol PCR conditions 
A) PCR reaction conditions and PCR program used in MPRA ssDNA OLS library amplification. B) 
PCR reaction conditions and PCR program used for amplicon sequencing of MPRA plasmid 
library after CRE insertion. 
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Table 2.4 – MPRA PCR primer sequences 
ssDNA oligos used for MPRA library PCR reactions. See table 2.3 for reaction conditions. 
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3 CHAPTER 3  
3.1 Introduction 
Pathogen detection by pathogen recognition receptors (PRRs), such as the Toll-
like receptors (TLRs) and the RIG-I-like receptors (RLRs), activate a network of 
transcription factors (TFs) that regulate host defense genes (Honda, Taniguchi, 
2006). The TFs interferon regulatory factor 3 (IRF3), IRF5 and IRF7 (IRF3/5/7) are 
central to PRR signaling in response to viruses and intracellular pathogens with 
distinct, yet overlapping, roles in host defense (Honda and Taniguchi, 2006; Lazear 
et al., 2013; Stetson and Medzhitov, 2006a, 2006b). IRF3/5/7 reside predominantly 
in the cytoplasm and upon PRR-induced phosphorylation they dimerize and 
translocate to the nucleus to promote gene transcription (Barnes et al., 2002; 
Honda et al., 2006). Upon activation, IRF3/5/7 induce both common and factor-
specific target genes (Barnes et al., 2002; Cheng et al., 2006; Honda et al., 2006; 
Tamura et al., 2008), but they can also function antagonistically (Barnes et al., 
2002; Negishi et al., 2012). For example, IRF3 can repress (IFNA10, IFNA22) or 
enhance (IFNA1, IFNA7) IRF7-dependent gene activation (Barnes et al., 2002). 
Despite their central role in the response to pathogens, little is known about the 
mechanisms by which IRF3/5/7 target overlapping gene programs. 
IRFs share a conserved N-terminal DNA-binding domain that recognizes a 
consensus 5’-AANNGAAA-3’ DNA sequence found upstream of many virus- and 
IFN-inducible genes (Honda and Taniguchi, 2006). Activated IRF3/5/7 function as 
dimers that recognize the longer composite dimer site 5’-A/GNNGAAANNGAAA-
3’ (Figure 3.1A), referred to as the IFN-stimulated response element (ISRE) 
(Tamura et al., 2008). Despite a shared ability to bind to consensus binding 
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elements, the inherent DNA-binding differences between IRF3/5/7 may partially 
account for regulatory differences (Cheng et al., 2006; Tamura et al., 2008; Yanai 
et al., 2007). In virus-infected BJAB lymphoma cells, expression of exogenous 
IRF5 or IRF7 induced 568 and 630 target genes, respectively (Barnes et al., 2004); 
however, only 371 (approx. 60%) of the genes were induced by both proteins, 
suggesting that DNA-binding differences led to alternate target genes. Similarly, 
studies examining the regulation of the type I IFNs by IRF3/5/7 have revealed 
inherent DNA-binding and regulatory differences for each factor, and attributed 
regulatory differences to dimer-specific binding to the viral-response elements 
(VREs) in the type I IFN gene promoters (Barnes et al., 2004; Civas et al., 2006; 
Génin et al., 2009; Yeow et al., 2000). The full extent of IRF3/5/7 DNA-binding 
differences and their impact on dimer-specific gene regulation remains unclear. 
To better understand the scope of IRF3/5/7 DNA-binding differences and their role 
in defining dimer-specific target genes, we have used protein-binding microarrays 
(PBMs) to characterize the DNA-binding landscape of IRF3/5/7 dimers We used 
constitutively dimeric, phosphomimetic mutants of IRF3 (Chen et al., 2008a; Marié 
et al., 2000; Ren et al., 2014; Ryzhakov et al., 2015; Takahasi et al., 2010), IRF5 
(Cheng et al., 2006) and IRF7 (Caillaud et al., 2005) (Figure 3.1B) to best 
characterize the active dimeric form of the IRF proteins. We examined the binding 
of IRF3/5/7 homodimers to thousands of ISRE-type elements to characterize both 
common and dimer-specific DNA binding features. To explore the role of binding 
affinity in the regulation of type I IFN genes, we characterized IRF3/5/7 binding to 
the VREs of all human and mouse type I IFN genes. Finally, integrating our PBM 
data with gene expression data, we relate DNA binding affinity to gene regulatory 
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specificity. Our results provide new insights into the role and limitations of affinity 
as a distinguishing mechanism of IRF3/5/7 gene expression and function. 
3.2 Results 
3.2.1 Characterizing IRF3/5/7 dimer binding with PBMs 
PBMs are double-stranded DNA microarrays that enable the in vitro measurement 
of protein binding to tens of thousands of unique DNA sequences (Berger et al., 
2006; Siggers et al., 2011). To examine the DNA-binding specificity of IRF3/5/7 we 
used custom-designed PBMs. We designed a PBM that included 10,044 IRF-type 
binding sites spanning a range of affinities, half-site sequences, and half-site 
spacing (Figure 3.1). To query base preferences across the IRF binding site, we 
designed the PBM to contain 162 distinct IRF binding sites and all possible single-
nucleotide variants (SNVs) across a 20-bp sequence centered on the IRF binding 
site (Figure 3.1A). This SNV-type PBM design allowed us to directly and 
comprehensively compare the base preferences of the IRF3/5/7 dimers across the 
IRF binding sites, and to construct position-weight matrix (PWM) descriptions of 
IRF3/5/7-DNA binding (Figure 3.1 D, Materials and Methods). 
PBM and other experiments were performed using phosphomimetic variants of 
IRF3(6D) (Chen et al., 2008a; Lin et al., 1999), IRF5(4D) (Cheng et al., 2006) and 
IRF7(8D)(Caillaud et al., 2005) that have been previously shown to form the active, 
homodimeric form of each protein (Figure 3.1B). Previous studies examining IRF 
binding used monomeric DNA-binding domains (DBDs) (Badis et al, 2009), or 
overexpressed the proteins in HEK293T cells in conditions not known to promote 
dimerization (Jolma, et al., 2013). Hereafter, the phosphomimetic proteins are 
  52 
referred to simply as IRF3, IRF5 and IRF7 (unless otherwise noted). The PBM 
experiments were performed with purified GST-tagged IRF3/5/7 homodimers at 
four concentrations, and relative binding constants (KPBM) were determined for 
each sequence (Chapter 2). We have previously shown this approach of 
integrating PBMs at multiple concentrations can reliably define relative protein-
DNA binding affinities (Siggers et al., 2011). Log(KPBM) values were transformed 
into z-scores based on the distribution of scores from 600 random DNA probes 
(i.e., a background set). We use z-scores to represent our PBM binding data. 
To assess the quality of our PBM experiments, we examined the z-scores for 
known in vivo IRF target sites and our ability to capture known dimer-specific DNA-
binding preferences. We find that known IRF binding sites are bound significantly 
better than the random background sequences (Figure 3.1C), demonstrating 
sensitivity in our assay. DNA-binding logos were constructed for the IRF dimers 
(Figure 3.1D; Chapter 2). While clear differences are evident for each IRF dimer, 
these logos agree with reported ISRE sites (Tamura et al., 2008) and logos 
generated from a high-throughput HT-SELEX assay (Jolma et al., 2013). 
The IRF5 logo from our PBMs resembles a half-site logo with a single core 5’-
GAAA-3’ element. This logo matches the HT-SELEX ‘monomer’ logo, as opposed 
to the ‘extended’ logo that resembles the full-length logos determined for IRF3 and 
IRF7 that appear to contain two 5’-GAAA-3’ elements (Figure 3.2) (Jolma et al., 
2013). For several reasons, we believe that this shorter logo represents a true 
dimer site but results from an IRF5 preference to engage more strongly to one 
ISRE half-site. First, if we relax the β parameter in our logo generation procedure 
(Figure 3.2, Chapter 2 - Materials and Methods), we see the correct 5’-GAAA’-3’ 
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preferences appearing in the 5-prime half of the logo. This suggests that both half-
sites are engaged by IRF5 proteins and that the base preferences are simply 
weaker for the 5-prime half-site. Second, with our SNV approach to logo 
generation, we can generate a binding logo for individual sites by altering the DNA 
base identities and monitoring the change in binding affinity. We find that while the 
majority of starting seed sequences (13/15) result in the shortened half-site logo 
(as in Figure 3.1), logos from a minority of seed sequences (2/15) appear longer, 
and match the extended-version of the IRF5 logo also identified by HT-SELEX. 
We find that these extended logos occur when the 5-prime half-site in the seed is 
a better match to the consensus 5’-GAAA-3’ than for the 3-prime half-site (e.g., 5’-
GAAANNGATA-3’). These observations suggest that IRF5 binds as a dimer with 
an asymmetric half-site preference. 
As a further confirmation of the PBM data, we compared PBM z-scores to electro-
mobility shift assays (EMSAs) for select high- and low-affinity binding sites (Figure 
3.3). We find that EMSAs qualitatively recapitulate the differential binding indicated 
by our z-scores: IRF3 z-scores 11.4 to 6.3 correspond to >25-fold change in affinity 
and 11.4 to 3.6 correspond to >100-fold change in affinity; IRF5 z-score 16.4 to 
2.2 correspond to >100-fold change in affinity; IRF7 z-scores 16.6 to 5.1 
correspond to > 50-fold change in affinity. These results demonstrate that our PBM 
data accurately captures the DNA-binding landscape of IRF3/5/7 dimers over a 
wide range of binding site affinities. 
3.2.2 Common and IRF-specific binding sites 
 To investigate the nature and extent of IRF3/5/7 binding differences we compared 
the PBM-determined binding profiles for the IRF dimers (Figure 3.4A). Consistent 
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with binding logo differences, we observed IRF-specific binding preferences 
indicated by ‘off-diagonal’ data points that represent sequences bound much better 
by one IRF dimer than another. For comparison, pseudo replicate IRF experiments 
showed no such off-diagonal data points (Figure 3.4B). DNA sequence 
preferences for the IRF dimers can be queried by examining the distribution of 
specific sequence subsets. For example, examining the z-score distribution of all 
sequences that contain IRF sites with the alternate 5’-GATA core elements (i.e., 
that match the pattern 5’-GATANNGATA-3’) we see clear dimer preferences 
(Figure 3.4C). Specifically, IRF7 cannot tolerate these alternate core elements 
and, therefore, all sequences in the IRF7 experiment have z-scores 
indistinguishable from background (i.e., z-score near zero). In contrast, both IRF3 
and IRF5 can bind sequences with this alternate core sequence. For IRF5, some 
of these 5’-GATA sequence variants score among the highest in our dataset; 
however, this is not the case for IRF3 indicating that IRF5 is more tolerant of this 
alternate core element. Pairwise comparison of our PBM data revealed many 
differences between the IRF3/5/7 dimers. 
In general, base preferences that distinguish the DNA binding of IRF3/5/7 dimers 
from each other are apparent in their respective DNA-binding logos (Figure 3.1D). 
For example, based on the logos, IRF3 appears more tolerant than IRF5 of base 
variants at most positions; however, this difference is most apparent at position 11 
where IRF5 highly prefers a Cyt base. We can directly confirm this selectivity by 
analyzing our PBM data and identifying single-base changes (i.e., SNVs) that 
abrogate binding of IRF5 but not IRF3. We identified 8 such IRF5-abrogating SNVs 
in our PBM dataset, and all were C-to-G changes at position 11. For example, 5’-
CCGAAACCGAAACC-3’ was bound highly by both IRF3 (z-scores 10.9) and IRF5 
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(z-score 14.8), but the SNV 5’-CCGAAACGGAAACC-3’ was bound well by IRF3 
(z-score 8.2) but not by IRF5 (z-score 2.9). Base differences at position 11 largely 
explain the bifurcation seen in the PBM data (Figure 3.4C) in which IRF5 is bound 
poorly to a number of DNA sites that are bound with high affinity by IRF3. In a 
similar manner, we examined the selection against IRF7 binding observed in 
Figure 3C for the 5’-GATANNGATA-3’ sequences. Comparing the logos of IRF5 
and IRF7, we see that IRF7 is primarily more base selective at positions 7 and 8, 
suggesting that SNVs at these positions differentially affect IRF5 and IRF7. We 
identified 50 sequence pairs in which a SNV abrogates IRF7 binding but does not 
perturb high-affinity IRF5 binding: 41/50 SNVs were A-to-C,G or T changes at 
position 8, which disrupts the IRF7-preferred Ade base, and 2/50 SNVs were A-to-
T changes at position 7. For example, IRF5/7 both bound to 5’-
CCGAAACCGAAACC-3’ with high affinity (z-scores 16.6 and 16.4, respectively), 
but the SNV 5’-CCGACACCGAAACC-3’ was bound well by IRF5 (z-score 13.6) 
but not by IRF7 (z-score 4.2). Unexpectedly, we also found 5 A-to-T SNVs at 
position 14 were selective against IRF7, but not readily expected from the logo 
comparisons. For example, IRF5/7 both bound to 5’-CCGATACCGAAACC-3’ with 
high affinity (z-scores 14.9 and 9.8, respectively), but the SNV 5’-
CCGATACCGATACC-3’ abrogated IRF7 binding (z-score 2.2) while IRF5 was 
largely unaffected (z-score 12.0). This IRF5 (and IRF3) tolerance for a Thy at 
position 14 is indicated by a slightly weaker Ade selectivity in the logo. Pairwise 
comparison of IRF3/5/7 logos and our SNV binding data reveal features of 
IRF3/5/7 binding specificity that distinguish the separate dimers and highlight the 
impact that genomic SNPs may have on relative IRF3/5/7 binding and function. 
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Despite the binding differences observed for the IRF dimers, we observe common, 
high affinity binding sites shared by all three proteins. For example, the IRF high 
affinity probe (Figure 3.1C) is a top-scoring sequence for each IRF dimer and is 
consistent with the known canonical ISRE element. This shared specificity 
landscape for close paralogs, in which both common and dimer-specific binding 
sequences are observed, has been reported for a number of transcription factor 
paralog families (reviewed in (Andrilenas et al., 2015)). The existence of shared 
and dimer-specific sites provides a potential mechanism for the IRF dimers to 
regulate both common and dimer-specific genes. 
3.2.3 Alternate ISRE half-site spacing 
IRF3/5/7 binding has been reported for binding sites with both the canonical 2-bp 
spacer between each 5’-GAAA-3’ half-site, as well as with a 3-bp spacer, hereafter 
referred to as 2- and 3-bp sites (Escalante et al., 2007; Panne et al., 2007). 
However, DNA-binding logos determined using our PBM dataset (Figure 3.1), 
other in vitro methods such as HT-SELEX (Jolma et al., 2013), or learned from 
ChIP-seq datasets (Freaney et al., 2013) support a dominant 2-bp site. The X-ray 
crystal structure of IRF3 and IRF7 bound to the IFNB gene promoter demonstrates 
the binding of alternate IRF3 and IRF7 DBDs that support binding to both a 2-bp 
site (Figure 3.5A, PRDIII) and an adjacent 3-bp site (Figure 3.5B, PRDI). 
Therefore, we sought to determine whether IRF dimers could bind to both 2-bp 
and 3-bp sites with similar affinities, and whether specific IRF dimers have 
individual preferences. 
We first examined the binding of the IRF3/5/7 dimers to the variant ISRE elements 
found in the IFNB promoter for which there is structural evidence for binding to 
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both 2- and 3-bp sites. The X-ray crystal structure supports a simple model of two 
adjacent IRF3-IRF7 heterodimers bound to the adjacent PRDIII (2-bp) and PRDI 
(3-bp) sites, P1 and P3, respectively (Figure 3.5A). However, there is a third 
possible ISRE element (P2) that spans these canonical elements (Figure 3.5A). 
We used PBMs to assay the binding of the IRF3/5/7 dimers to all three possible 
ISRE sites (Figure 3.5 A). We find that IRF3 and IRF7 bind well to both the proto-
typical ISREs PRDIII and PRDI, and IRF5 binds well to PRDI. Notably, all three 
dimers bind most strongly to the 3-bp PRDI site. While we cannot determine the 
binding register from our PBM data (i.e., whether canonical residues contact the 
same positions in the 5’-GAAA-3’-type half-site), X-ray crystal structures 
(Escalante et al., 2007; Panne et al., 2007) suggest IRF dimers bind to the PRDI 
site in a 3-bp binding register. These results demonstrate that, in the context of the 
IFNB promoter, the 3-bp PRDI site is the highest affinity IRF binding site. 
Therefore, a description of IRF-DNA binding that does not include 3-bp sites will 
fail to capture functional binding sites. 
To determine the impact of the spacer length on IRF binding, we examined the 
binding of IRF3/5/7 to 120 matched pairs of 2-bp/3-bp ISRE sites. Matched pairs 
differ by a single base in the spacer between half-sites (i.e., GAAANNGAAA -> 
GAAANXNGAAA, Figure 3.5 B). We find that altering the spacing from 2- to 3-bp 
lowers the binding affinity for all three IRF dimers by a similar amount (mean delta 
z-score ~ 5.0)( Figure 3.5B). These data suggest an explanation for the canonical 
2-bp PWMs (i.e., binding models) described in the literature (Freaney et al., 2013; 
Jolma et al., 2013; Mathelier et al., 2016) — 2-bp sites are higher affinity. However, 
despite the lower binding affinity to 3-bp binding site variants, we find that many 3-
bp sites in our dataset score well above background. For example, IRF7 binds to 
  58 
559 of 3456 3-bp IRF site variants with z-scores > 4.0. Therefore, many 3-bp sites 
in the genome are likely of sufficient affinity to be functional (e.g., PRDI in the IFNB 
promoter). 
Previous studies (Dragan et al., 2007; Panne et al., 2007) have also proposed an 
alternate binding mode in which IRF dimers are bound to half-sites 8-bp apart (e.g., 
5’-GAAA(N)8GAAA-3’). The extended binding conformation would allow IRF 
proteins to reside on the same side of the DNA helix(Panne et al., 2007) (Figure 
3.5C). We examined the binding of IRF3 to this extended site by electro mobility 
shift assay (EMSA)(Figure 3.5C). We found that IRF3 binding to an 8-bp extended-
dimer site was at least 100-fold weaker than to a sequence-matched 2-bp site. 
These results reaffirm that the preferred binding mode for IRF dimers is to closely-
spaced half-sites (i.e., 2-bp and 3-bp sites), and not to an extended dimer site (i.e., 
8-bp site). 
3.2.4 Differential dimer binding to type I IFN gene VREs 
IRF3/5/7 regulate the type I IFN genes (Honda et al., 2006; Stetson and Medzhitov, 
2006a; Tamura et al., 2008) that coordinate immunity to viruses and other 
intracellular pathogens (Honda et al., 2006; Stetson and Medzhitov, 2006a). The 
type I IFN genes consist of IFNB and multiple IFNA genes (Figure 3.6). IRF3 and 
IRF7 are the primary type I IFN regulators (Honda et al., 2006, 2005; McNab et al., 
2015); however, IRF5 can also regulate select IFNs (Tamura, Yanai, Savitsky, 
Taniguchi, 2008). Induction of the type I IFNs in virus-infected cells is primarily a 
consequence of IRF regulatory input from the promoter VREs (Génin et al., 2009; 
Honda and Taniguchi, 2006). Despite their central role in IFN gene regulation, it 
remains unclear to what extent DNA-binding of IRF3/5/7 differs across the VREs. 
  59 
To address the role of DNA binding in type I IFN gene regulation, we used PBMs 
to measure the binding of IRF3/5/7 to the promoters of all type I IFN genes from 
human and mouse. We measured dimer binding to all potential IRF binding sites 
found in the 250-bp immediately upstream of the IFN genes that encompasses the 
VREs, these regions were selected because of their density of IRF-binding sites 
(VREs) and the sequence space constraints of the PBM platform. Considering only 
significant binding sites (PBM z-score > 4.0), we found there was little binding to 
the regions outside of the VRE; therefore, we have focused our analysis on the 
VREs. 
For both human and mouse, we observe binding for IRF3 and IRF7 to multiple 
sites within the VREs (Figures 3.6A and 3.6B). Studies have delineated sub-
elements (A/B, C and D) within the IFN VREs that play critical but different roles in 
IFN regulation (Civas et al., 2006, 2002; Génin et al., 2009; Yeow et al., 2000) 
(Figures 3.6A and 3.6B). We find differences in IRF3 and IRF7 binding profiles 
across the various VREs sub-elements. IRF3 and IRF7 bind with similar, though 
not identical, patterns to the VRE-C and VRE-D elements. However, they differ 
strongly in their binding to VRE-A/B elements — IRF7 binds VRE-A/B in most 
VREs (20/27), whereas IRF3 binds in only three (3/27). It has been proposed, 
based on studies of mouse Ifna4 and Ifna2 genes (Civas et al., 2002), that late-
phase expression of IFNA genes is controlled by Irf7 binding to VRE-A/B, whereas 
early-phase expression is controlled by Irf3 binding to VRE-C. We show that for 
many IFNs (63%, 17/27) it is only IRF7 that binds to VRE-A/B, suggesting that late-
phase expression driven by IRF7-VRE-A/B binding may be a common regulatory 
feature for most IFNs. The sequence logo for IRF sites in the human and mouse 
VRE-A/B (Figure 3.7) does not indicate a simple explanation for the IRF7 binding 
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preference over IRF3. In contrast, we find that the majority of VRE-C elements are 
bound by both IRF3 and IRF7, with only the VRE-C of the mouse Ifna4 and Ifnab 
genes showing IRF3-exclusive binding, suggesting that the regulatory logic of 
early-phase IFN expression from VRE-Cs is more complicated. 
Unexpectedly, we observed a near complete lack of IRF5 binding to the IFNA 
VREs. IRF5 does not bind to any human VREs, and only binds three mouse VREs 
(Figures 3.6A and 3.6B). As a control, we see strong IRF5 binding to regulatory 
loci for other IRF target genes, such as IFNB (Barnes et al., 2002), IL10 
(Krausgruber et al., 2011), and CXCL10 (Honda and Taniguchi, 2006) (Figure 
3.6C). The lack of IRF5 binding to the VREs is broadly consistent with the less 
prominent role described for IRF5 in the regulation of the IFNA genes (Honda and 
Taniguchi, 2006; McNab et al., 2015; Tamura et al., 2008). However, given the 
large number of IRF binding site variants that can be bound strongly by all three 
IRF dimers (Figure 3.4A), it is striking that the IRF binding site variants from human 
and mouse VREs would maintain their inability to bind to IRF5. The sequence logo 
for IRF sites in the human and mouse VRE regions (Figure 3.7) highlights the 
sequence variability across individual sites and suggests a mechanism for the 
observed absence of IRF5 binding. There is a nearly complete absence of Cyt 
bases at positions 11 and 16 flanking the 5’-GAAA-3’ core that are both highly 
preferred by IRF5 (Figure 3.1). The evolutionarily conserved absence of IRF5 
binding suggests a selective pressure against IRF5 binding to these loci that is 
based on selective use of binding sites variants bound preferentially by IRF3/7 
(addressed more below). 
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3.2.5 A single amino acid dictates the IRF binding selectivity to IFNA VREs 
To investigate how IRF5 binding is selected against in the VREs, we examined the 
multiple protein sequence alignment for IRF3/5/7 to find potential specificity-
altering residues. We reasoned that residues critical to distinguishing IRF3/5/7 
binding specificity would (i) vary between all three IRFs (but would be conserved 
between human and mouse orthologs), and (ii) make base-specific contacts with 
DNA. Based on protein-DNA interactions defined in available IRF3 and IRF7 
crystal structures (Escalante et al., 2007; Panne et al., 2007), we found three 
residues that fit these criteria (Figure 3.6E). We examined the IRF sites within the 
IFNA VREs and determined that selection against IRF5 binding was most likely 
due to DNA sequence features 3-prime to the canonical 5’-GAAANNGAAA-3’ 
ISRE sequence; therefore, we chose to examine the residue position in alpha helix 
α3 shown to contact DNA bases in this region (Figure 3.6E, red highlight). Given 
that IRF7 and IRF5 exhibited the largest differences in their binding profiles across 
the IFNA VREs, we made mutants in which we swapped orthologous residues 
between IRF5 and IRF7 — IRF5(K96S) and IRF7(S101K). 
We examined the DNA binding of the IRF5(K96S) and IRF7(S101K) mutants by 
PBM experiment. Binding logos generated for the mutants revealed that the amino 
acid alterations at this position neatly swapped the DNA binding specificity for IRF5 
and IRF7 at the 3-prime end of the DNA binding sites (Figure 3.6D). Mutations at 
this position had the effect of making IRF5 more tolerant of alternate bases in this 
region, while making IRF7 less tolerant (e.g., strong selectivity for a cytosine at 
base position 16). Examining the binding of the mutant IRFs to the IFNA VREs 
(Figure 3.6A and 3.6B), we found that IRF7(S101K) had drastically reduced 
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binding across the VREs compared to IRF7, while IRF5(K96S) showed increased 
binding compared to IRF5. These results identify this residue position in helix α3 
(Figure 3.6E) as a key determinant of IRF binding specificity that can alter the base 
preferences in the 3-prime flanks of the canonical ISRE. Furthermore, base 
contacts mediated by residues at this position are critical for the selective binding 
of IRF7 over IRF5 across the IFNA VREs. Therefore, poor binding of IRF5 to VREs 
is partially explained by the bases flanking the core ISRE elements that are 
unfavorable for interaction with IRFs containing a lysine residue at this position in 
the DBD (i.e., IRF5 and IRF7 S101K). 
3.2.6 Binding affinity contributes to ISRE function and selectivity 
We next sought to determine the extent to which IRF3/5/7 binding differences 
translate into IRF-specific gene regulation. We examined whether IRF3/5/7-
specific binding site variants discovered in our dataset would drive IRF-specific 
gene activation. Dimer-specific binding site variants (I3, I5, I7) that show 
preferential binding to IRF3, IRF5 or IRF7, respectively, were chosen from the 
PBM data (Figures 3.9A, 3.9B). To relate our findings to IFNA gene regulation, we 
examined the impact of these site variants on gene expression in the context of 
the 250-bp human IFNA14 promoter. We observed no significant IRF binding to 
the IFNA14 VRE in our PBM experiments (Figures 3.6A, 3.6B), and others have 
similarly reported no IRF3/7 binding to this element (Yeow, Au, Juang, Fields, 
Dent, Gewert, Pitha-Rowe, 2000); therefore, it provided a useful promoter context 
in which to examine the impact of binding site variants on gene expression. Binding 
site variants were inserted simultaneously into the VRE-C and VRE-D elements of 
the IFNA14 promoter and we examined the ability of each variant promoter to drive 
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reporter gene expression in the presence of constitutively active IRF dimers: 
IRF3(6D), IRF5(4D) and IRF7(6D) (Figure 3.9 A). For reporter gene experiments, 
IRF7(6D) was used instead of IRF7(8D) as it is a stronger activating dimer 
(Caillaud, Hovanessian, Levy, Marie, 2005). 
We found that dimer-specific binding sites can promote dimer-specific gene 
activation. Promoters with IRF3- and IRF5-specific sites (I3, I5) were selectively 
activated by IRF3 and IRF5, respectively (Figure 3.9 B,C). However, affinity-
independent mechanisms also appear to contribute to IRF binding site function. 
Promoters with IRF7-specific sites (I7) were strongly activated by IRF7 but, 
unexpectedly, also by IRF5 (Figure 3.9 B,C). Furthermore, IRF5 drove expression 
from the I7 promoter at a 4.1-fold higher level than for the I5 promoter, despite the 
fact that IRF5 binds to I7 with lower affinity than to I5 (z-scores 3.4 and 10.7, 
respectively). We do not believe that heterodimerization with endogenous IRF 
proteins contributes to our observation that affinity does not correlate with activity. 
IRF3 and IRF7 are expressed at low levels in our WT and transfected HEK293T 
cells (Figure 3.8); however, in our unstimulated cell-culture conditions IRF proteins 
are not known to be active. Furthermore, we observe very low reporter gene 
activation with eGFP transfected in place of our active IRF dimers, suggesting that 
the endogenous IRF3/7 are not active and would not contribute to gene 
expression. These data show that IRF3/5/7-specific gene activation depends on 
both affinity and affinity-independent mechanisms.  
We next tested whether ‘common’ binding sites bound by all three IRF dimers 
would be functional for each dimer. We found that IRF3/5/7 all drove reporter gene 
expression from the C-2 promoter bound with high affinity by all three IRFs (Figure 
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3.9B, C). However, expression from the C-2 promoter was not the highest for any 
of the IRFs, despite C-2 being the highest-affinity binding site for all three IRF 
dimers (Figure 3.9 B). For example, IRF7-stimulated expression was 6.1-fold lower 
from the C-2 promoter than from the I7 promoter despite having a much higher 
binding affinity (z-score 17.0 versus 9.5). This diminished activity for the C-2-
promoters suggests that for IRF3/5/7 dimers high-affinity binding may depress 
gene activation (discussed more below).  
3.2.7 Affinity-independent mechanisms of ISRE function 
To understand affinity-independent mechanisms of ISRE function, we first 
investigated whether ISRE half-site spacing contributed to IRF-dependent reporter 
activity. We compared the activity of binding site variants that differed only in their 
half-site spacer length (i.e., 2-bp versus 3-bp sites). Specifically, we compared the 
activity of a 2-bp (I7-2) and 3-bp (I7) version of our IRF7-specific site, and a 2-bp 
(C-2) and 3-bp (C-3) version of a high-affinity site common to IRF3/5/7 (Figure 3.9 
A). These matched pairs of binding-site variants differed only by a single base in 
the spacer sequence (Figure 3.9 D). 
Spacer variants for the common high-affinity sites (C-2 and C-3) actually led to 
similar reporter activity levels for all three IRFs (Figure 3.9E), despite the fact that 
all IRFs bind with lower affinity to the C-3 variant (Figure 3.9 D). Similarly, spacer 
variants for the IRF7-specific site (I7-2, I7) also led to similar expression levels for 
IRF7 despite lower binding affinity to the 3-bp variant.  This surprising congruence 
in activity for IRF-binding-site spacer variants suggests that either (1) 3-bp sites 
are more functionally active and can make-up for a lower binding affinity; or (2) 
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that DNA-sequence features, which are virtually identical between spacer pairs, 
are critical to the activity level of IRF sites.  
Additional promoter comparisons clarify that DNA-sequence features beyond 
spacer length influence the activity of IRF binding sites. First, binding sites with 
similar IRF binding affinity can exhibit different activity: C-3 and I7 have similar 
IRF7 binding affinity (z-scores 11.2 and 9.5), and the same spacer lengths, but I7 
induces 6.5-fold higher gene activation (Figure 3.9 D, E). Second, we noted that 
the wild-type IFNA14 promoter, intended as a control in our assay, is activated by 
IRF7 despite low binding affinity to the WT-C and WT-D sites on PBM (z-scores < 
4.0) (Figure 3.9 D,E). These data support a model in which IRF-site DNA sequence 
features, beyond half-site spacing, contribute to the regulatory activity of an IRF 
site in an affinity-independent manner.  
To determine the DNA sequence features of IRF binding sites that may affect their 
activity, we compared the DNA sequences of the variant sites tested in reporter 
assays (Figure 3.9 A). The I7-2 and C-2 sites promote different levels of gene 
activation (from 2.6-fold for IRF3 to 6.1-fold for IRF7) despite having identical core 
ISRE sequences — C-2 and I7-2 share an identical 5’-CCGAAACCGAAA-3’ core. 
Furthermore, the most transcriptionally active of these sites, I7-2, is lower affinity 
than C-2. This differential activity and DNA sequence similarity indicates that DNA 
bases flanking the 12-bp core element can modulate the transcriptional activity of 
an IRF site even at the expense of binding affinity. 
3.3 Limitations 
In this study we systematically characterized the DNA-binding landscapes of 
homodimeric IRF3/5/7 proteins, using PBMs, and examined the impact of small 
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variations in IRF binding sites on reporter gene expression. While our results 
provide new insights into the potential role of affinity as a distinguishing 
mechanism of IRF3/5/7 gene expression and function, this research is not 
without limitations. 
First, a notable limitation of the PBM platform is that it is is an in vitro protein-
DNA binding assay that does not approximate the cellular transcription factor 
(TF) DNA binding environment of the nucleus. TF-DNA binding and 
transcriptional regulation in the nucleus involves complex 3D changes in genome 
architecture as well as recently described changes in matter-phase from a liquid 
to gel surrounding enhancer regions (Shrinivas et al., 2019). These changes in 
matter state may cause localized changes in protein concentration and pH 
generally altering interaction kinetics. These conditions are not captured by 
current in vitro binding assays including PBMs and EMSAs. Additionally, in vitro 
protein-DNA binding experiments rely on conditions that are not found in the cell 
nucleus. Notably PBMs utilize printed spots of DNA with many copies of each 
DNA molecule closely packed and covalently linked to a glass slide. This 
environment likely alters the movement of DNA and adds constraints to the 
accessibility of a DNA molecule by a TF in comparison to a DNA molecule in 
solution. Despite these limitations, PBMs provide protein-DNA binding affinity 
data in agreement with other in vitro methodologies and allow the high-
throughput measurement TF-DNA binding (Badis et al., 2009; Berger et al., 
2006, 2008; Linnell et al., 2004; Siggers et al., 2012a). Furthermore, DNA-
binding motifs derived from in vivo methodologies exhibit striking agreement with 
in vitro-defined DNA-binding motifs, suggesting that DNA binding specificity in 
vivo adheres to basic biophysical parameters that can be determined reliably 
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using these in vitro methods. However, deviations form in vitro and in vivo results 
occur and provide opportunities for identifying novel mechanisms of specificity; 
therefore, we believe that careful in vitro biophysical characterization, and 
comparison of these results to in vivo experiments, is a necessary step in 
understanding the mechanisms of TF regulatory specificity. 
An additional limitation that may impact the interpretation of our data is the use of 
E. Coli expressed IRF3/5/7 proteins. Exogenous expression of IRF3/5/7 and 
subsequent affinity tag purification produced heterogenous protein samples with 
multiple degradation products. The heterogeneous nature of these protein 
samples is visually apparent in the IRF EMSAs present in this chapter (Figures 
3.3, 3.6). The multiple bands present in the IRF EMSAs likely represent mixtures 
of full-length IRF proteins dimerized with those that have lost their GST affinity 
tags. IRF monomers bind DNA with approximately 200-fold lower affinity than a 
constitutively active phosphomimetic IRF3 (Kd 1226 (WT) vs. Kd 5.8 (IRF3-5D)) 
Dragan:2007ga}, so they are unlikely to be present in the bands in our EMSAs. 
Another aspect of E. coli-based protein production that can impact the function of 
expressed human proteins is the lack of mammalian post-translational 
modifications (PTMs). Fortunately, IRF3/5/7 are only known to be modified in 
response to innate immune stimulation (phosphorylation) or for suppression of 
the IRF-dependent immune response via ubiquitination or acetylation. 
In our mutational study of the structural determinants of IRF5 specificity we found 
that the IRF7-S101K and IRF5K96S mutants largely swapped DNA binding 
patterns, however the changes in specificity were incomplete. Additional amino 
acids near the residue we mutated may confer additional selectivity if they were 
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mutated at the same time. IRF5-S97 and IRF7-T102 are additional residues that 
uniquely vary between IRF3/5/7, future studies examining the structural 
determinants of IRF DNA-binding could mutate these and check for complete 
conversion in specificity.  
We chose to use phosphomimetic IRF proteins in our PBM and EMSA 
experiments in part due to concerns regarding the heterogeneity in producing 
large quantities of purified, phosphorylated IRFs. IRF3/5/7 protein samples used 
on the PBM were challenging to produce and the addition of a phosphorylation 
step would likely increase the heterogeneity of the samples. We were also 
interested in making systematic measurements of IRF3/5/7 DNA-binding affinity 
and chose not to use stimulated cell lysates in our PBM experiments to 
guarantee that observed differences in IRF3/5/7 DNA binding were due to 
inherent differences between the proteins rather than due to potential cofactor 
interactions. Additionally, given the complex regulation of the IRFs in both a cell-
type and stimulus specific manner, finding stimulation conditions that similarly 
activate IRF3, IRF5 and IRF7 may be impossible. We chose to over-express our 
phosphomimetic IRF constructs in reporter assays to standardize comparisons 
between our PBM data and our reporters. 
Studies of phosphomimetic IRFs show that they are constitutively active and 
dimeric; able to interact with transcriptional coactivators (i.e. CBP); and 
recapitulate IRF dependent gene regulation in both reporter assays and gene 
expression assays. Despite this, these constitutively active IRF mutants are a 
convenient experimental tool that may fail to capture the full impact of post-
translational modifications (PTMs) (e.g. phosphorylation, acetylation, etc.) on IRF 
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regulation. For example, in the paper characterizing the crystal structure of the 
IRF5 dimerization domain, Chen et al. (2008) suggest that the IRF5-S436D 
phosphomimetic (S462D in our construct) may not fully recapitulate dimer 
stabilizing effects hypothesized to occur with serine phosphorylation at that site 
(Chen et al., 2008b; Marié et al., 2000; Ren et al., 2014; Ryzhakov et al., 2015; 
Takahasi et al., 2010). Additionally, acetylation and ubiquitination are known to 
impact IRF7dependent gene regulation by suppressing the DNA-binding activity 
of IRF7 (acetylation) and flagging IRF7 for degradation. These are PTMs that are 
beyond the scope of our research, but are integral to the regulation of IRF7 
activity and no mimetic mutants are known to recapitulate the effects of these 
PTMs. However, we are confident that the DNA-binding specificity of these E. 
coli produced IRF dimers provides a metric by which to compare the individual 
dimers and to connect inherent DNA binding differences with in vivo regulatory 
differences.  
Heterodimer formation is an aspect of IRF3/5/7 DNA-binding activity that may 
have important implications for IRF DNA-binding and IRF-dependent gene 
regulation. IRF3, IRF5 and IRF7 have been shown to interact via 
immunoprecipitation western blots (Barnes et al., 2003) and it is suggested that 
IRF3/5/7 heterodimers regulate the expression of IFNβ and the IFNα genes 
(Honda and Taniguchi, 2006) . We hypothesize that heterodimer formation 
between IRF5 and either IRF3 or IRF7 could expand (Honda and Taniguchi, 
2006b; Suhara et al., 2000; Wathelet et al., 1998)the DNA-binding repertoire of 
IRF5 allowing it to bind more strongly to the IFNα proximal promoters. We did not 
perform heterodimer PBM studies in part due to the potential complexity of 
interpreting heterogeneous mixtures of IRF5:IRF3/7 heterodimers and each 
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respective IRF homodimer that may spontaneously form depending on the 
interaction kinetics of IRF heterodimers versus IRF homodimers. In future 
experiments examining IRF5:IRF3/7 heterodimer binding, the IFNα subset of IRF 
binding sites would be specifically informative. Given the notable lack of strong 
IRF5 binding to these sites, any significant increase in IRF5 binding could be 
attributed to heterodimer formation or potentially some form of indirect 
recruitment of IRF5 by IRF7, although there is no evidence for this kind of IRF 
homodimer indirect recruitment in the literature. These heterodimer PBM 
experiments would require testing IRF specific antibodies on the PBM, or 
producing IRF proteins with different epitope tags for detection.  
Another context not captured in our in vitro experiments is the impact of 
chromatin state on IRF binding. Chromatin state is an essential component of 
gene regulation that dictates which genes are available as TF gene targets 
(Medzhitov and Horng, 2009). The PBM platform is unable to assess the impact 
of chromatin state on TF-DNA binding interactions. In general, biochemical 
protein-DNA-binding assays like PBMs, EMSAs, HT-SELEX and others, are 
unable to assay the impact of chromatin state on TF binding. Chromatin 
immunoprecipitation sequencing (ChIP-seq) is a well-known method for 
measuring chromatin state and TF-DNA interactions. ChIP-seq data can provide 
a snapshot of TF genome occupancy as well as chromatin state differences like 
histone modifications associated with enhancers and promoters. ChIP-seq 
provides broad TF occupancy windows that subsequently require TF binding site 
analysis. This limitation necessitates follow up using detailed biochemical 
methods such as PBMs and EMSAs to verify and characterize TF binding to 
generate a mechanistic model of TF dependent gene regulation. PBMs can 
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incorporate ChIP-seq data to examine how genomic TF binding sites may be 
differentially bound. Unfortunately for our analysis of IRF3/5/7, there are few 
ChIP-seq data sets for these proteins. ChIP-seq data is dependent on finding 
antibodies with strong affinity and avidity. The lack of high-quality antibodies is a 
known problem in the IRF research field, exemplified by a paper that only 
assesses the variable quality of IRF5 targeted antibodies on the market (Li et al., 
2016). 
3.4 Discussion 
IRF3/5/7 are central regulators of the host-defense program to pathogens (Honda 
and Taniguchi, 2006; Lazear et al., 2013; Stetson and Medzhitov, 2006a). Here, 
we addressed the ability of inherent IRF3/5/7 DNA-binding differences to define 
dimer-specific gene regulation. We characterized the DNA-binding preferences of 
IRF3/5/7 homodimers, and identified both common and dimer-specific DNA-
binding preferences. We demonstrate that dimer-specific binding sites can 
promote dimer-specific reporter gene expression, showing that sufficient DNA-
binding differences exist for IRF3/5/7 to induce unique target gene sets. We also 
found that affinity-independent mechanisms contribute to IRF3/5/7 binding site 
activity and, therefore, may also contribute to dimer-specific gene regulation 
(discussed more below). Currently, there are no genome-wide chromatin 
immunoprecipiation (ChIP) studies for IRF7 and IRF5 that would allow a 
comparison of in vivo IRF3/5/7 binding to our PBM data. Specifically, there are no 
ChIP studies for IRF7, and the single IRF5 study (Saliba et al., 2014) found no 
ISRE motif enriched in the IRF5-bound ChIP peaks, suggesting that under the 
conditions assayed IRF5 does not function as a canonical DNA-bound dimer. 
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Genome-wide binding studies for activated IRF3/5/7 dimers would help to clarify 
whether the inherent DNA-binding differences described here, and in other studies 
(Jolma et al., 2013), define the distinct global binding patterns and gene regulatory 
programs for IRF3/5/7.  
IRF3/5/7 are central regulators of type I IFN expression, and the host-defense 
response to viruses and intracellular pathogens (Honda et al., 2006; Stetson and 
Medzhitov, 2006a; Tamura et al., 2008). To understand the role of DNA binding in 
IFN regulation, we mapped the binding of IRF3/5/7 dimers to all human and mouse 
IFN gene VREs. We found that IRF3 and IRF7 bind across many of the VRE sub-
elements, but that the VRE-A/B sub-element is bound almost exclusively by IRF7. 
This suggests that the previously described role for IRF7-VRE-A/B binding to 
control late-phase IFN expression (Civas et al., 2002) is common to many IFN 
genes. Examining the landscape of IRF3/5/7 binding to the individual ISRE sites 
within the VREs, we find that for the 61 sites bound by at least one IRF dimer 93% 
(57/61) bound to IRF7, 60% (37/61) bound to IRF3, and only 5% (3/61) bound to 
IRF5. These data support the current understanding that IRF3 and IRF7 are the 
primary regulators of the type I IFNs (Honda and Taniguchi, 2006; Tamura et al., 
2008).  
The most striking results from our analysis of the type I IFN VREs was absence of 
IRF5 homodimer binding to all human and most mouse VREs. Our PBM binding 
data (Figure 3.5) demonstrate that there are many IRF site variants that can be 
bound by all 3 IRF dimers; therefore, the conspicuous absence of IRF5 binding to 
VREs from two evolutionarily distant species suggests that there has been 
selection against IRF5 homodimer binding to these loci. We demonstrate that a 
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single amino acid difference between IRF7 and IRF5 was critical to their differential 
binding profiles across the VREs. Furthermore, this amino acid altered the binding 
preference for DNA bases immediately 3-prime to the canonical ISRE site (Figure 
3.6D). Therefore, IRF5 homodimer binding to the VREs is inhibited by the 
evolutionary retention of specific ISRE variants with 3’-flanking bases that are 
unfavorable for IRF5.  
IRF5 can regulate specific IFNA genes in a cell- and stimulus-specific manner 
(Barnes et al., 2003, 2001; Tamura et al., 2008; Yanai et al., 2007). Furthermore, 
IRF5 forms heterodimers with IRF3, and IRF3 can enhance the recruitment of IRF5 
to IFNA promoters in virus-infected cells (Barnes et al., 2003, 2001). This suggests 
that IRF3:IRF5 heterodimers are the dimer species critical for IRF5-dependent 
regulation of the IFNA genes, as opposed to IRF5 homodimers, which we find do 
not bind well to IFNA VREs. We propose that a heterodimer of IRF3:IRF5 could 
avoid the unfavorable IRF5 binding that we observe if the 3’-end of the binding site 
was occupied by IRF3. In other words, heterodimerizing with IRF3 would allow 
IRF5 to bind the VREs by avoiding the non-optimal half-site sequence. Future 
studies with IRF heterodimers should further clarify these selection rules for IRF 
proteins for the IFNA VREs.  
Finally, analyzing the role of DNA-binding affinity in IRF3/5/7-dependent gene 
regulation revealed clear affinity-independent mechanisms. We found that DNA 
sequence features of IRF binding sites could enhance their activity even at the 
expense of binding affinity. Comparison of sequence variants revealed that these 
differences did not need to occur in the core ISRE motif, but could be in the flanking 
bases. For example, the C-2 and I7 sites have identical 5’-CCGAAACCGAAA-3’ 
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core sequences yet very different IRF7 binding affinity (z-scores 17.0 and 9.5, 
respectively) and IRF7-dependent gene expression activity (6.1-fold higher for I7) 
(Figure 3.9). The mechanism of this uncoupling of affinity and activity remains 
unclear. However, a plausible mechanism is DNA-based allostery, in which IRF 
dimers adopt alternate protein conformations based on the DNA sequence of the 
binding sites and these structural differences affect gene activation. DNA-based 
allostery has been described for other factors, such as glucocorticoid receptors 
(Meijsing et al., 2009; Watson et al., 2013) and NF-κB (Wang et al., 2012), where 
in certain situations affinity and activity do not correlate. Future studies should 
clarify these details and provide a clearer picture of how affinity-dependent and 
affinity-independent mechanisms regulate IRF activity. The PBM dataset of IRF 
binding sites sequences and affinities generated here will provide an invaluable 
framework for dissecting the roles of affinity and activity.  
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Figure 3.1 - PBM-based Analysis of IRF3/5/7 DNA Binding. 
(A) Schematic of IRF dimers and PBM probe design. (B) Phosphomimetic IRF variants used in 
our PBM experiments. Positions of Ser/Thr to Asp mutations are indicated. (C) PBM z-score 
distributions for IRF dimer binding to 10,044 synthetic SNV probes. Highlighted are z-scores for 
literature described IRF binding sites and a high-affinity consensus site bound by all three IRF 
dimers. (D) PBM-derived DNA-binding logos for IRF3/5/7. 
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Figure 3.2 - Seed-sequence and Parameter-dependence of IRF DNA-binding Logos. 
(A) IRF5 binding logos from HT-SELEX experiments and PBM are compared. PBM-derived IRF5 
binding logos are shown for two separate b parameter values to illustrate the impact of this 
parameter on the binding logos. (B) IRF5 binding logos generated using our SNV approach 
(Chapter 2 - Methods) from select seed sequences are shown. DNA sequence of the starting 
seeds is indicated and the core half-site elements are in bold. Two separate types of logo (or 
motif) are identified and represented: a dominant motif for which base selectivity appears 
predominantly in one half-site, and an alternate motif that show base selectivity across the whole 
ISRE. 
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Figure 3.3 - DNA-binding of IRF3/5/7 to Select ISREs. 
EMSAs for IRF3, IRF5 and IRF7 on select DNA sequences from our PBM experiments. PBM z-
scores for the DNA sequences used in EMSA experiments are included. Estimated fold-
differences in binding affinity are indicated for different DNA sequences. DNA probe 
concentrations of 1 nM were used in all experiments. The C-2 PBM probe is bound with high-
affinity by IRF3, IRF5 and IRF7 compared to IFNβ PRD3 element. Refer to Table 2.2 for EMSA 
probe sequence. 
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Figure 3.4 - IRF3/5/7 DNA-binding Preferences. 
(A) Pairwise comparison of z-scores for IRF3, IRF5 and IRF7 binding to 10,044 synthetic IRF 
sites (black dots) and 644 random background sequences (blue dots). (B) Pairwise comparison 
of PBM z-scores (same sequences as in (A)) for IRF7 performed at two single concentrations 
(i.e., pseudo-replicate experiments). (C) Shown are the same pairwise comparison data as in (A) 
with all binding sequences matching the pattern 5’-GATANNGATA-3’ (N is any base) highlighted 
in red.  
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Figure 3.5 - IRF3/5/7 Binding to ISREs with Alternate Half-site Spacing.  
(A) Binding of IRF3/5/7 to binding sites found in the PRDI and PRDIII elements of the IFNB 
promoter. Two sites (P1, P2) have a 2-bp spacer between GAAA-type half-sites (2-bp sites); one 
site (P3) has a 3-bp spacer. Error bars show the standard deviation of PBM-based z-scores to 5 
replicate DNA probe sequences (z-score for each individual sequence was determined by fitting 
to experiments at different concentrations as described in Materials and Methods). (B) Differential 
binding (i.e., delta z-scores) of IRF3/5/7 to identical sets of 120 sequence-matched 2- and 3-bp 
sites that differ by a single base (as shown in schematic). A schematic is shown illustrating how 
the ‘delta z-score’ for each sequence-matched pairs is calculated. The delta z-score distribution 
for all 120 sequence pairs is shown for IRF3/5/7. (C) EMSAs are shown for IRF3 binding to 3 
DNA site variants: (Monomer) — a single ISRE half-site (i.e., 5’-AANNGAAA-3’); (Proximal dimer) 
— site with a 2-bp spacer between half-sites (2-bp site); (Extended dimer) — site with an 8-bp 
spacer between half-site (8-bp site). (D) Schematic illustrating the proposed binding arrangement 
of an IRF dimer to the site variants.  
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Figure 3.6 - Wild-type and Mutant IRF Dimer Binding to IFNA VREs.  
(A) Binding profiles of wild-type and mutant IRFs to human IFNA VREs. Binding sites are 
illustrated as 10-bp blocks in register with the canonical 5-GAAANNGAAA-3’ elements of an IRF 
binding site. Low-affinity binding sites (z-score < 4.0) are not shown (see chapter 2). Z-scores for 
each panel range from 0 to 13.0. IFNA gene names are shown. Coordinates for VREs elements 
are available upon request. (B) Binding profiles to mouse IFNA VREs are shown, all details as in 
(A). (C) Binding profiles of wild-type IRF3/5/7 to known IRF-binding regulatory elements are 
shown. Profile details as in (A,B). Coordinates for regulatory element DNA sequences are 
available upon request. (D) DNA-binding logos for wild-type and mutant IRF5/7 are shown. Wild-
type logos are identical to those in Figure 1 and are shown for contrast. Regions in which the 
DNA base specificity is altered in the mutant IRFs are highlighted with red shading. DNA logos 
generated as described in Materials and Methods (i.e., SNV approach). (E) Multiple protein-
sequence alignment for human and mouse IRF3/5/7 is shown. Alignment is limited to the portion 
of protein containing alpha helices 2 and 3 that contains the base-contacting residues that match 
our criteria to be specificity determining (see main text). Identically conserved residues across all 
IRFs are indicated with a ‘ * ‘; residues in which IRF3/5/7 are different (but conserved across 
species) are indicated with a ‘ | ‘. Putative specificity-determining residues are highlighted with 
shaded bars; our selected specificity-determining residue is highlighted in red.  
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Figure 3.7 - DNA-binding Logos Compiled for ISREs from IFNA VREs. 
Logos representations are shown for all binding sites bound by IRF3, IRF5 or IRF7 in mouse and 
human IFNA VREs (as in Figure 3.6). Logos were compiled independently for the sites found in 
VRE-A/B (20 sites), VRE-C (19 sites) and VRE-D (22 sites), as shown in Figure 3.5. Logos for 
sites from mouse and human VREs were compiled together.  
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Figure 3.8 - IRF Protein Levels in Transfected HEK293T Cells. 
Phosphomimetic IRF protein overexpression levels were assessed using dual-color fluorescent 
western blot analysis. 30 µg of whole-cell lysate was loaded per condition, with 25ng of purified 
IRF3/5/7 protein as a positive control. HEK293T plates were PEI transfected as described in the 
main methods section with 7.2 µg of plasmid DNA consisting of: pGL4.54 TK-Luciferase [2.48 
µg]; E1a-eGFP [1.99 µg]; pDEST26 IRF3/5/7 or additional E1a-eGFP [0.25 µg]; pGEM3zf(-) 
carrier DNA [2.48 µg], these quantities are scaled up from 96-well plates assuming a 20µg typical 
10cm plate transfection. (A) IRF3 immunodetection shows the overexpression of His-IRF3-6D 
protein as well as low ubiquitous levels of endogenous IRF3 present in all conditions. (B) IRF5 
immunodetection shows an absence of IRF5 in HEK293T cells and a strong overexpression of 
His-IRF5-4D protein. (C) IRF7 immunodetection shows basal expression of IRF7 in HEK293T 
cells; however, the levels of endogenous IRF7 are similar in all transfection conditions with an 
increase in IRF7 signal in the His-IRF7-6D overexpression condition. 
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Figure 3.9 - Comparison of DNA Binding and Gene Activation by ISRE Variants 
(A) Schematic for promoter variants based on IFNA14 VRE. Promoter variants contain 
simultaneous alterations of C-site and D-site with the binding site shown in the box. Wild-type C-
site (WT-C) is shown for context. (B, D) PBM-determined z-scores are shown for IRF3/5/7 to 
binding site sequence variants listed in (A). Error bars are calculated as in Figure 3. (C, E) 
Reporter gene activation levels for promoter variants in HEK293T cells over-expressing the 
phosphomimetic, constitutively active IRF dimers: IRF3(6D), IRF5(4D) and IRF7(6D). Normalized 
fold-induction (relative to I7-2 promoter levels) is shown for each promoter. Mean and standard 
error of the mean (sem) values were calculated over at least 15 replicate measurements. 
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Figure 3.10 – Reporter assay luciferase (pGL4.54) plots 
Bar plots showing the mean of the luciferase (constitutive transfection control plasmid) data. Error 
bars show standard deviation. 
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Figure 3.11 – Reporter assay nano luciferase plots 
Bar plots showing mean nano luciferase data (experimental reporter plasmid), error bars show 
standard deviation.  
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Figure 3.12 – Reporter assay transfection normalized data plots (Norm) 
Bar plots showing reporter assay data normalized to the luciferase constitutive transfection 
control plasmid, error bars represent standard deviation. C-2 and C-3 constructs in the GFP 
control condition show elevated background expression levels. This may be due to other 
transcription factors utilizing those sites. Final reporter assay data was normalized to the GFP 
signal to account for this background expression. (see Figure 3.13) 
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Figure 3.13 – Reporter assay GFP normalized fold-induction plot (gfp_norm) 
Bar plots show reporter assay activity relative to GFP (no IRF) expression, error bars represent 
standard deviations. GFP expression condition was used to place the cells under 
transcriptional/translational load to control for the impact of exogenous protein expression. 
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Figure 3.14 – Reporter assay data scaled to i7-2 reporter condition 
Bar plots show reporter assay data scaled to each protein condition’s respective i7-2 activity, 
error bars represent standard deviation. This aesthetic scaling was used to simplify the final plots 
in Figure 3.9 without altering the relationships between data within a protein condition.  
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Table 3.1 – Reporter assay luciferase data descriptive statistics 
Table includes descriptive statistics of raw luciferase values (transfection control plasmid) for 
each Protein by Reporter condition. Values are in counts per minute as measured on the Victor-3 
luminometer (see Chapter 2 – Materials and Methods) 
 
 
  
luc luc luc luc luc luc luc luc
count mean std min 25% 50% 75% max
Protein Reporter
GFP C-2 28 3103.714286 1692.09077 558 1725.75 2840.5 3838.25 6536
GFP C-3 15 2620.466667 1146.293896 1118 1668.5 2464 3340.5 4650
GFP empty 30 3071.4 1532.397324 617 2077.75 2867 3973 6796
GFP i3 27 4100.518519 2865.232054 624 1376.5 4214 5895 12500
GFP i5 24 3076.5 2010.252699 889 1500.75 2769.5 3995 8496
GFP i7 30 3556.133333 1842.746577 1202 2128 2955.5 4863.75 7310
GFP i7-2 21 2968.52381 1586.142447 490 1736 2830 3949 6322
GFP wt 24 3502.833333 2546.467659 1060 1452 2523.5 4644 9204
IRF3 C-2 24 1275.541667 629.6927463 356 829 1124 1442 2836
IRF3 C-3 12 1199.416667 447.7705294 682 826.25 1106 1479.75 1994
IRF3 empty 21 1072.190476 307.2556947 538 863 1069 1250 1689
IRF3 i3 21 1184.952381 842.2655446 238 544 940 1447 2855
IRF3 i5 18 1069.944444 595.0555557 383 617.5 854.5 1666 1943
IRF3 i7 23 1030.347826 384.0456423 337 771.5 1012 1218.5 1857
IRF3 i7-2 18 1141.833333 560.3042503 582 743.75 975.5 1328.75 2728
IRF3 wt 21 1161.285714 712.6125976 183 515 1074 1648 2365
IRF5 C-2 21 1342.52381 705.7898143 421 945 1146 1778 2883
IRF5 C-3 15 1249.533333 320.5100548 619 1070 1317 1454.5 1716
IRF5 empty 18 1198.388889 523.3633468 521 756.75 1125 1671.25 2098
IRF5 i3 18 1242.722222 740.5358001 423 615.5 1288.5 1604.5 2794
IRF5 i5 15 1261.2 497.5959635 459 869 1236 1702.5 1942
IRF5 i7 21 1119.904762 465.3776858 399 806 1059 1293 2203
IRF5 i7-2 21 1484.809524 1023.100465 592 885 1129 1651 4321
IRF5 wt 18 1064.944444 514.3484139 365 694.75 873 1443.75 2121
IRF7ss C-2 30 2463.166667 1261.822521 914 1598 2132 3192.5 5672
IRF7ss C-3 15 1999.266667 1196.863906 705 1175.5 1772 2244.5 4950
IRF7ss empty 29 2195.172414 1134.396538 625 1306 2033 3120 4496
IRF7ss i3 27 2872.37037 1803.820713 441 1450 2325 3968.5 7901
IRF7ss i5 24 2558.25 1673.31967 498 1418.25 1980 3028.5 7067
IRF7ss i7 30 2415.233333 1341.68334 399 1619.75 2023.5 3069.75 6425
IRF7ss i7-2 21 2405.190476 1494.838574 1018 1350 1601 2808 5708
IRF7ss wt 27 3702.925926 3695.934522 583 1452 2222 3763.5 15117
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Table 3.2 – Reporter assay Nano Luciferase descriptive statistics 
Table includes descriptive statistics of raw nano-luciferase (experimental plasmid) values for each 
Protein by Reporter condition. Values are in counts per minute as measured on the Victor-3 
luminometer (see Chapter 2 – Materials and Methods) 
 
 
  
nanoluc nanoluc nanoluc nanoluc nanoluc nanoluc nanoluc nanoluc
count mean std min 25% 50% 75% max
Protein Reporter
GFP C-2 28 27708.28571 23255.87968 4568 15724 21461 28180 95890
GFP C-3 15 13716.13333 5349.121502 5754 8985 13818 16578 25486
GFP empty 30 2822.2 1222.662369 852 2131.5 2703 3231.5 7142
GFP i3 27 4189.037037 3181.714795 782 1452 3542 5425 12548
GFP i5 24 1721.166667 911.6347317 512 738.5 1754 2323 3408
GFP i7 30 3631.133333 1769.548915 1146 2188.5 3445 4809 8602
GFP i7-2 21 7256.952381 3365.72094 1564 4526 7088 10402 13530
GFP wt 24 1887.333333 1163.183139 478 705 1871 2640 4066
IRF3 C-2 24 6686215.667 2010767.399 2555500 4974042.5 6945031 8208645.5 10033316
IRF3 C-3 12 4893898 1442698.312 2386476 3850968.5 5403095 5866845.5 6745832
IRF3 empty 21 4473.142857 2427.861246 1590 3166 4060 5182 13770
IRF3 i3 21 1421754.857 839131.5405 281964 793520 1365136 1765130 3255692
IRF3 i5 18 3775.777778 2444.465527 1008 1606.5 3411 4925.5 9748
IRF3 i7 23 73786.17391 42063.0415 16040 43420 61200 102430 177110
IRF3 i7-2 18 5418433.444 1326723.979 3601574 4353113 5469694 6413292 7929744
IRF3 wt 21 10457.04762 6969.10194 874 4512 10106 15788 25604
IRF5 C-2 21 3370415.905 1229622.92 1721484 2332178 3375162 3939652 5931760
IRF5 C-3 15 2830400.8 1046073.005 1003706 1881219 2870008 3634919 4520668
IRF5 empty 18 4646.555556 2005.127757 2650 3088 4116 5369.5 10130
IRF5 i3 18 28469 20988.30106 10946 16227 21780 33507.5 99282
IRF5 i5 15 149502.5333 56713.02961 66310 115130 124946 181441 251660
IRF5 i7 21 1095387.333 536056.1616 391214 753732 869882 1410814 2419864
IRF5 i7-2 21 4150362.095 1622474.933 1929346 3118698 4052008 4527678 7731834
IRF5 wt 18 3529.222222 2075.673684 802 2184 3014 5118.5 7788
IRF7ss C-2 30 1866511.733 1712772.654 287814 713546.5 1202476 2585748.5 7138636
IRF7ss C-3 15 1120946.8 1125848.596 50812 353057 429608 1942815 3338332
IRF7ss empty 29 3130.965517 1101.670111 1318 2168 3050 4064 5000
IRF7ss i3 27 8902.740741 11032.02802 698 2496 3682 11912 44372
IRF7ss i5 24 2548.916667 1877.589387 288 930 1970 3992 5850
IRF7ss i7 30 1670716.2 1517504.273 79054 602573.5 1215045 2241068 6162902
IRF7ss i7-2 21 3063626.19 1798373.428 535758 1875526 2518114 4114868 6866174
IRF7ss wt 27 1145561.333 1457078.708 10904 118233 473918 1925630 5554786
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Table 3.3 – Reporter assay transfection control normalized data 
Table includes descriptive statistics of transfection control normalized (NanoLuc/Luc) values for 
each Protein by Reporter condition. Values are ratios of NanoLuc/Luc (see Chapter 2 – Materials 
and Methods) 
 
  
norm norm norm norm norm norm norm norm
count mean std min 25% 50% 75% max
Protein Reporter
GFP C-2 28 8.847857035 3.219177098 4.262851897 6.583614497 8.566555258 9.884390095 15.70454545
GFP C-3 15 5.431336883 0.98654193 3.584435798 4.930410673 5.694323144 6.200391582 6.787337662
GFP empty 30 1.278804577 1.324831644 0.366118837 0.64123896 0.995949805 1.122473561 5.694779116
GFP i3 27 1.0566312 0.253425062 0.566030606 0.920817594 1.047549378 1.172687049 1.622746186
GFP i5 24 0.628816964 0.336402693 0.348809524 0.468663215 0.517197589 0.608135722 1.892287234
GFP i7 30 1.081111399 0.347190717 0.575262055 0.781590122 1.060041618 1.284082354 1.710479221
GFP i7-2 21 2.603662076 0.689136396 1.577534586 2.125347329 2.360062893 3.019448476 4.179859989
GFP wt 24 0.568648003 0.17933598 0.328062182 0.450857761 0.504061421 0.663483999 1.027716674
IRF3 C-2 24 6669.709601 3648.334615 901.0930889 4497.622026 5710.181977 9030.016237 14781.52174
IRF3 C-3 12 4280.399519 1165.846931 2912.227371 3335.985644 3916.501538 5116.513041 6433.681768
IRF3 empty 21 4.714935996 2.994735037 1.5 2.5296 4.1882805 5.53888131 12.08955224
IRF3 i3 21 1286.463099 304.245254 875.8092199 1004.541667 1227.25 1506.273625 1906.883312
IRF3 i5 18 3.47682443 1.003295617 2.195758564 2.753195433 3.064827483 4.006265976 5.914951989
IRF3 i7 23 73.653328 38.82979273 28.28924162 42.90702347 62.17210682 88.94619815 168.5156993
IRF3 i7-2 18 5320.527038 1639.127305 2802.031646 3738.84485 5405.784991 6650.355465 8004.529492
IRF3 wt 21 9.745340625 5.333039116 3.552845528 5.413297394 8.463519313 14.88645262 21.28128342
IRF5 C-2 21 2823.644956 880.5467198 1619.922697 2046.722716 2789.390083 3778.486993 4435.2827
IRF5 C-3 15 2275.782718 652.4343189 1178.613333 1777.731808 2567.683801 2715.528331 3108.950472
IRF5 empty 18 4.337295352 2.057487506 1.991202346 2.930305083 3.825063372 4.812677103 8.555743243
IRF5 i3 18 23.93927107 6.846288819 11.2826496 21.14994536 25.56957381 27.86947462 35.53400143
IRF5 i5 15 125.5458627 31.61367346 66.76363636 114.811658 131.4990893 144.2896322 168.7131012
IRF5 i7 21 1010.89998 319.5865456 441.3404363 830.9 1002.297767 1209.054381 1489.132832
IRF5 i7-2 21 3316.522713 1200.08695 1789.362185 2032.865109 3905.557676 4341.614865 4931.025989
IRF5 wt 18 3.214332339 0.927389069 1.858778626 2.645689849 2.977250394 3.800734095 5.3371266
IRF7ss C-2 30 729.5491368 484.085535 192.7733836 405.9285783 588.4876348 975.0366333 2295.042265
IRF7ss C-3 15 515.5713424 465.7979523 59.14153439 241.8835053 409.5878788 457.5926459 1511.241286
IRF7ss empty 29 1.851408288 1.238589017 0.402135231 1.103448276 1.440572792 2.08984726 5.506775068
IRF7ss i3 27 2.44211573 1.503908414 1.042044518 1.321720271 1.817945384 2.82655869 5.615997975
IRF7ss i5 24 1.089082084 0.809928957 0.338797814 0.58104423 0.694851868 1.516473023 3.674347158
IRF7ss i7 30 646.5916696 472.9532218 60.89069374 326.6190421 473.3589806 941.6262052 1801.900943
IRF7ss i7-2 21 1593.920676 1146.075789 422.7014716 526.2848723 1282.28732 2783.207945 4110.977987
IRF7ss wt 27 251.3902109 228.5084693 18.70325901 94.01968037 198.6856072 363.1106355 797.2493529
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Table 3.4 – Reporter assay GFP transfection normalized data 
Table includes descriptive statistics of GFP control normalized (Reporter with IRF/Reporter with 
GFP) values for each Protein by Reporter condition. Values are ratios showing the fold activity of 
a reporter with IRF over its corresponding GFP control. (see Chapter 2 – Materials and Methods) 
 
  
gfp_norm gfp_norm gfp_norm gfp_norm gfp_norm gfp_norm gfp_norm gfp_norm
count mean std min 25% 50% 75% max
Protein Reporter
GFP C-2 28 1 0.133844143 0.80669904 0.887153543 0.995228142 1.040677008 1.30479454
GFP C-3 15 1 0.158421816 0.772507343 0.890100226 1.012772376 1.090856654 1.40528319
GFP empty 30 1 0.28518211 0.53872407 0.855121801 0.978546493 1.078667971 1.864761327
GFP i3 27 1 0.202062847 0.709090822 0.867097693 0.950547788 1.102240891 1.524724173
GFP i5 24 1 0.231901606 0.493057559 0.892679154 0.987517385 1.06466807 1.581868319
GFP i7 30 1 0.246478843 0.506419891 0.837444064 0.975643373 1.129358809 1.499302599
GFP i7-2 21 1 0.185770047 0.686371339 0.902326579 0.958316165 1.155947892 1.385024226
GFP wt 24 1 0.195636156 0.658131872 0.839095153 0.962117862 1.195119307 1.351314755
IRF3 C-2 24 805.9005182 338.0716455 186.9078327 584.3899646 867.5251569 1013.990102 1408.061472
IRF3 C-3 12 763.7682662 210.5630705 512.0964031 605.2677423 683.9754084 966.1672329 1091.002607
IRF3 empty 21 3.599570888 1.259156271 1.950445034 2.51201248 3.276583541 4.307475591 5.871610726
IRF3 i3 21 1229.405309 367.994617 845.9520425 970.2958766 1135.449965 1380.17153 2192.373069
IRF3 i5 18 6.295637145 1.60915675 4.140946116 5.24143953 5.656898034 7.325301104 10.00860014
IRF3 i7 23 71.40315421 36.21365608 24.90384086 49.36610598 55.08555289 95.33786051 156.718623
IRF3 i7-2 18 2035.5864 643.3341416 1137.779941 1514.682935 2013.656658 2465.941537 3173.63503
IRF3 wt 21 16.05925388 7.438961588 7.398837255 10.22471606 13.1341662 20.16813102 31.94349067
IRF5 C-2 21 320.4181412 51.75808341 229.4121249 277.9845097 325.9981326 359.931951 422.497142
IRF5 C-3 15 419.070192 119.4214688 254.0113719 319.0787718 419.2734 507.9706327 601.3873938
IRF5 empty 18 3.229574785 1.094405792 1.585455205 2.176822697 3.492685931 4.081646161 4.854413892
IRF5 i3 18 23.06507759 5.299854547 14.25464533 20.87159275 23.39697318 25.13352105 34.62661599
IRF5 i5 15 219.7997455 93.92154232 51.53346525 204.5813485 239.9703525 274.4797035 341.9352521
IRF5 i7 21 901.9453599 263.2940065 506.9869802 679.726701 915.756164 1084.405634 1310.926873
IRF5 i7-2 21 1287.859755 483.0767785 726.5800887 827.1839545 1190.887093 1699.992632 2255.918095
IRF5 wt 18 5.364321049 1.76121893 3.032375138 4.389290901 4.776284854 5.660936029 9.031518168
IRF7ss C-2 30 90.24182339 57.41065909 24.0640019 44.02925934 74.75708472 121.0996669 228.9614173
IRF7ss C-3 15 91.70673241 71.88875662 10.03399156 46.78932398 81.7131446 96.05723117 240.5170065
IRF7ss empty 29 1.715038916 0.958684852 0.591720247 1.295781721 1.459815524 1.86528705 4.707274938
IRF7ss i3 27 2.297324931 1.251133853 0.85470871 1.484843127 1.761098558 2.798645802 4.518048738
IRF7ss i5 24 1.656442977 0.86318309 0.638933404 1.104665621 1.390584908 1.850670388 3.785873826
IRF7ss i7 30 637.455357 480.4697319 48.77851978 300.7262728 484.4712773 879.3574741 1675.757426
IRF7ss i7-2 21 574.6637128 317.2459928 171.6401941 213.7007882 590.8466619 835.6324714 1234.283159
IRF7ss wt 27 455.0835679 357.1957461 31.18505095 195.7969487 281.3834612 764.1612064 1115.20361
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Table 3.5 – Reporter assay data scaled to i7-2 reporter condition 
Table includes descriptive statistics of i7-2 reporter scaled data used in reporter assay figures 
(gfp_norm/gfp_norm_i7-2) values for each Protein by Reporter condition. Values are ratios 
scaling the data to the i7-2 experimental condition to simplify figures given the range of reporter 
activities seen across IRF proteins. (see Chapter 2 – Materials and Methods) 
 
 
  
i72_scale i72_scale i72_scale i72_scale i72_scale i72_scale i72_scale i72_scale
count mean std min 25% 50% 75% max
Protein Reporter
GFP C-2 28 1 0.133844143 0.80669904 0.887153543 0.995228142 1.040677008 1.30479454
GFP C-3 15 1 0.158421816 0.772507343 0.890100226 1.012772376 1.090856654 1.40528319
GFP empty 30 1 0.28518211 0.53872407 0.855121801 0.978546493 1.078667971 1.864761327
GFP i3 27 1 0.202062847 0.709090822 0.867097693 0.950547788 1.102240891 1.524724173
GFP i5 24 1 0.231901606 0.493057559 0.892679154 0.987517385 1.06466807 1.581868319
GFP i7 30 1 0.246478843 0.506419891 0.837444064 0.975643373 1.129358809 1.499302599
GFP i7-2 21 1 0.185770047 0.686371339 0.902326579 0.958316165 1.155947892 1.385024226
GFP wt 24 1 0.195636156 0.658131872 0.839095153 0.962117862 1.195119307 1.351314755
IRF3 C-2 24 0.395905828 0.166080715 0.091820142 0.28708679 0.426179482 0.498131694 0.691722775
IRF3 C-3 12 0.375207982 0.103440989 0.251571932 0.297343184 0.336009028 0.474638283 0.535964775
IRF3 empty 21 0.001768321 0.000618572 0.000958174 0.001234049 0.001609651 0.002116086 0.002884481
IRF3 i3 21 0.603956338 0.180780642 0.415581497 0.476666516 0.557799937 0.678021591 1.077022852
IRF3 i5 18 0.003092788 0.000790513 0.002034277 0.002574904 0.002779002 0.00359862 0.004916814
IRF3 i7 23 0.035077437 0.017790282 0.012234234 0.02425154 0.02706127 0.046835576 0.076989423
IRF3 i7-2 18 1 0.316043643 0.558944558 0.74410152 0.989226819 1.211415805 1.559076554
IRF3 wt 21 0.007889252 0.003654456 0.003634745 0.005022983 0.006452276 0.009907774 0.015692525
IRF5 C-2 21 0.24879894 0.040189223 0.1781344 0.215849986 0.253131703 0.279480704 0.328061453
IRF5 C-3 15 0.325400488 0.092728629 0.197235274 0.247758943 0.325558275 0.394430085 0.466966525
IRF5 empty 18 0.002507707 0.000849786 0.001231078 0.001690264 0.002712008 0.003169325 0.003769365
IRF5 i3 18 0.017909619 0.004115242 0.011068476 0.016206417 0.01816733 0.019515728 0.026886946
IRF5 i5 15 0.17067056 0.072928393 0.040014811 0.158853748 0.186332675 0.213128567 0.26550659
IRF5 i7 21 0.700344394 0.204443074 0.393666297 0.527795592 0.711068236 0.842021525 1.017911204
IRF5 i7-2 21 1 0.375100454 0.564176407 0.642293504 0.924702467 1.320013787 1.751679938
IRF5 wt 18 0.004165299 0.001367555 0.002354585 0.003408206 0.0037087 0.004395615 0.007012812
IRF7ss C-2 30 0.157034143 0.099903053 0.041874929 0.076617434 0.130088403 0.210731362 0.398426788
IRF7ss C-3 15 0.159583301 0.125097087 0.017460632 0.081420356 0.142192978 0.167153814 0.418535225
IRF7ss empty 29 0.002984422 0.001668254 0.001029681 0.002254852 0.002540295 0.003245876 0.008191356
IRF7ss i3 27 0.003997686 0.002177158 0.00148732 0.002583847 0.003064572 0.004870058 0.007862074
IRF7ss i5 24 0.002882456 0.001502066 0.001111839 0.001922282 0.002419824 0.003220441 0.006587981
IRF7ss i7 30 1.109266764 0.836088518 0.084881851 0.523308269 0.8430518 1.530212287 2.916066194
IRF7ss i7-2 21 1 0.552055029 0.298679367 0.371871032 1.028160729 1.454124304 2.147835563
IRF7ss wt 27 0.791912831 0.621573519 0.054266609 0.340715699 0.489648911 1.329753714 1.940619505
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4 CHAPTER 4 - MASSIVELY PARALLEL REPORTER ASSAYS 
4.1 MPRA Overview 
Massively parallel reporter assays (MPRAs) use high-throughput sequencing to 
simultaneously measure the transcriptional activity of many thousands of cis-
regulatory elements (CREs). MPRAs achieve this scale by quantitating mRNA 
abundance transcribed from a complex pool of reporter plasmids after transfection 
into cells. Every CRE construct in the MPRA plasmid pool is identified by a 
sequence barcode embedded in the plasmid’s 3’-untranslated region (3’-UTR). 
This transcribed barcode is a key feature of MPRAs and results in reporter mRNAs 
that identify which CRE induced their expression. After mRNA extraction, CRE-
associated barcodes are quantified using RNA-seq and normalized to the CRE 
plasmid abundances. By using high-throughput sequencing, systematic 
comparisons of many CREs can be performed at a scale that would be prohibitive 
using low-throughput luciferase assays.  
4.2 Proposed IRF-MPRA experimental design 
The relationship between transcription factor DNA-binding affinity and 
transcriptional activity is complex and requires protein-specific empirical testing 
(Mulero et al., 2017). The Interferon Regulatory Factor (IRF) MPRA library 
described herein was designed to test the relationship between in vitro DNA 
binding affinity and IRF-dependent transcriptional regulation in cells. The IRF-
MPRA design leverages IRF DNA-binding affinity data from PBM experiments 
(Andrilenas et al., 2018) to dissect IRF-dependent transcriptional regulation in a 
systematic manner. This IRF-MPRA experiment is intended to be tested in 
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immune-activated cells (e.g., THP-1s with immune ligand stimulation) or cell lines 
expressing activatable or constitutively active IRFs of interest.  
The highly parallel nature of MPRAs allows multiple experimental hypotheses to 
be tested at once. Included in this MPRA library are multiple binding site 
experiments designed to test different aspects of IRF-dependent gene regulation 
such as: the relationship between DNA binding affinity and transcriptional activity 
and the impact of binding site spacing on reporter expression. The experiments 
included in the IRF-MPRA design are described below. 
4.2.1 MPRA design to assay the impact of Single Nucleotide Variants 
(SNVs) on IRF-dependent gene expression  
To interrogate the impact of single nucleotide variation on IRF-dependent gene 
regulation we designed sets of regulatory elements that include every possible 
single nucleotide variant (SNV) of four different IRF binding sites (Figure 4.1). 
Nearly all IRF binding sites in this design are included in PBM experiments 
discussed in Chapter 3. This allows for direct comparisons between MPRA 
transcriptional output and the PBM measured DNA-binding affinities of IRF3, IRF5 
and IRF7 to the SNV-modified IRF binding sites. To date, data directly comparing 
PBM derived protein:DNA-binding affinities and transcriptional regulation at the 
scale of MPRAs has not been generated, with most studies using binding models 
derived from HT-SELEX experiments or other methods (Hughes et al., 2018). We 
anticipate that the data generated from the SNV subset of the IRF-MPRA may 
elucidate details of the complex relationship between DNA-binding affinity and 
transcriptional output, and help to identify how DNA sequence can affect 
transcriptional activity and binding affinity differently.  
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The IRF-MPRA SNV design has multiple potential benefits. (1) SNVs are 
associated with changes in gene expression and health outcomes between people 
(Ghodke-Puranik and Niewold, 2015; Matta and Barnes, 2019); however, the 
mechanisms underlying the impact of SNVs seen in GWAS studies is not well 
understood. Systematically assaying the impact of SNVs on IRF-dependent gene 
expression may provide important insight into what SNVs may impact IRF gene 
regulation. (2) Using the SNV modeling approach used with IRF PBM data (chapter 
3) we can generate a PWM-motif illustrating IRF-dependent transcriptional output 
rather than DNA binding affinity (Andrilenas et al., 2018; Mohaghegh et al., 2019). 
By modeling the impact each SNV has on transcriptional output, we can provide 
an IRF DNA sequence logo that represents transcriptional regulation, which may 
differ from IRF DNA-binding affinity. (3) By measuring the impact of individual 
SNVs across IRF binding sites we can examine the regulatory consequences of 
subtle differences in DNA binding affinity found in PBM experiments (chapter 3). 
For example, IRF3/5/7 were shown to have decreased DNA binding specificity in 
the 5’ portion of their binding motifs (chapter 3). The MPRA data will allow the 
regulatory impact of this binding site asymmetry to be assayed, expanding our 
knowledge of IRF-dependent gene regulation. 
The SNV CREs included in this MPRA design are all in a conserved Viral 
Response Element (VRE)-like arrangement found in the promoters of the type-I-
interferon promoters that features two IRF binding sites with a small spacer (Figure 
4.2A,B) (Civas et al., 2006, 2002). Single binding site CREs are also included for 
a limited set of IRF binding sites in the form of binding site ablations discussed 
further below (Figure 4.3).  
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As part of the SNV experimental subset, multiple variants of the high-affinity 
common IRF binding site were included to explore the effects of different flanking 
sequences. Traditional reporter assays as, discussed in Chapter 3, suggest that 
flanking regions adjacent to the main binding site may influence gene expression 
(Andrilenas et al., 2018). We include the two flanking sequences interrogated in 
those assays (TAA and GTC) in our MPRA design. A non-consensus GATA half-
site core sequence is included to examine the effects of lower affinity half-sites on 
IRF-dependent gene expression. Figure 4.1B lists all starting sequences (seeds) 
used to generate SNV probes included in the IRF-MPRA design. 
4.2.1.1 Design to assay previously identified IRF homolog specific binding sites 
Protein binding microarray data (PBM) and luciferase reporter assay data (chapter 
3) identified a small set of IRF binding sites with increased IRF-homolog 
specificity(Andrilenas et al., 2018). These sequences have been included in the 
IRF-MPRA design to corroborate previous low-throughput studies and to provide 
known points of comparison between the existing data and this high-throughput 
design. The DNA-binding affinities for most of these sites have been measured 
using PBM (Figure 4.2C). 
4.2.1.2 Design to assay VRE ablation sequences 
As discussed in Chapter 1, many promoters of Interferon Regulatory Factor (IRF) 
driven genes feature a conserved “Viral Response Element” sequence structure 
featuring multiple IRF dimer binding sites (Barnes et al., 2002b; Civas et al., 2002). 
Numerous studies, including our own (Chapter 3) have explored the impact of 
altering IRF binding sites on transcriptional regulation; many have done so in a 
native or multi binding site context (Civas et al., 2006; Génin et al., 2009). The VRE 
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ablation design included in this MPRA design feature position matched ablations 
of IRF binding sites (Figure 4.3). These ablations were included to interrogate 
whether a single IRF binding site is sufficient to drive gene expression. This 
sequence design allows for the direct comparison of intact, sequence matched 
VRE regulatory elements to ablation VREs with either the Transcription Start Site 
(TSS)-distal or TSS-proximal binding site substituted with a “null” sequence (Figure 
4.2C).  
4.2.1.3 Design to assay IRF VRE binding site spacing on IRF-dependent gene 
expression 
The VRE cis-regulatory element is an important feature of IRF-dependent gene 
regulation that has been the focus of many studies (Civas et al., 2006; Génin et 
al., 2009). What remains unclear is the relationship between multiple IRF binding 
sites and whether IRF-driven gene expression requires a specific spacing between 
binding sites for efficient transcriptional activation. To explore this question, CRE 
plasmids that vary the length of the spacer between the IRF binding sites are 
included in this design. 
4.2.1.4 Design to assay the impact of binding site orientation on IRF-dependent 
transcriptional activity 
Intimate DNA-binding protein complexes like the Interferon Beta enhanceosome, 
suggest that transcription factor orientation is an important component of 
transcriptional complex assembly (Panne et al., 2007). At the same time, other 
studies find that TF binding site orientation has negligible impact on gene 
expression (Lis and Walther, 2016). The impact of IRF DNA-binding site orientation 
on transcriptional output has yet to be systematically assayed. To address this gap 
in the literature, we designed a subset of the IRF-MPRA design to include CREs 
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from other experimental subsets with the IRF binding sites reverse-complemented 
to change the orientation of IRF dimers that may bind. This design will allow the 
direct comparison between CREs with IRF binding sites in both orientations.  
4.3 MPRA technical design 
In brief, MPRAs require the construction of a complex plasmid library with 
thousands of unique members followed by transfection into cells and subsequent 
high-throughput DNA and RNA sequencing (Figure 4.4). This section provides a 
technical overview of the CRE-seq from plasmid library construction to sequencing 
and quantification. 
In MPRAs, the complex plasmid library containing the CREs being assayed, starts 
as an oligo pool often synthesized using microarray synthesis which allows for the 
customization of each member oligo (King et al., 2018; LeProust et al., 2010; 
White, 2015; White et al., 2016). We used Agilent OLS oligo pools (Agilent Inc.) 
which are delivered as 10 picomoles of single stranded DNA, which much be 
amplified via PCR and inserted into a modified mammalian expression vector 
backbone. An open reading frame containing a minimal promoter and the coding 
sequence for a characterized exogenous gene are inserted between the CRE and 
barcode (Figure 4.4). After integration, the barcode is contained within the vector 
sequence corresponding to the 3’ untranslated region of the mRNA that will be 
transcribed upon expression of the reporter gene. The MPRA plasmid library is 
transfected into cells and the resulting mRNA is extracted and sequenced. A 
critical aspect of the MPRA technique is the inclusion of the CRE-associated 
barcode within the mRNA that is produced from the expression plasmid library 
(King et al., 2018). The gene regulatory activity of a given CRE is quantitated by 
  106 
counting the number of reads that contain a specific barcode. These values are 
normalized by their representation in the MPRA plasmid library as determined by 
the barcode counts from the transfected MPRA plasmid pool. 
Our MPRA protocol is based on a detailed Cis-Regulatory Element Sequencing 
(CRE-seq) protocol shared by the Cohen Lab at Washington University, St. Louis, 
Missouri (King et al., 2018; Kwasnieski et al., 2012; White et al., 2016). 
Modifications have been made to improve key steps in the MPRA library cloning 
process as well as the inclusion of Unique Molecular Identifiers that have been 
used to improve RNA-seq quantitation in single-cell sequencing experiments 
(Zhang et al., 2019; Ziegenhain et al., 2017). The following sections delve into the 
technical decisions made while designing the IRF-MPRA experiment. 
4.3.1 Oligo library, cloning and plasmid design 
4.3.1.1 Complex oligo pools and library design 
As mentioned above, MPRA experiments begin as custom single stranded DNA 
(ssDNA) oligo pools that require PCR amplification before cloning into the target 
vector backbone. We sourced our starting MPRA oligo pool from Agilent, which is 
able to manufacture oligo pools with each oligo at a custom and independent 
length up to 210bp. The IRF-MPRA design contains 3,131 unique oligos with a 
maximum length of 153bp including cloning sequences and barcodes (Figure 4.5). 
We ordered a 15,000 oligo pool containing multiple independent MPRA subsets 
from different projects and used a subset specific primer strategy to facilitate 
multiplexing. To mitigate cloning contamination by multiplexed MPRA designs, 
subset-specific amplification primers were used. These primers were designed 
with specific attention toward potential PCR mispriming. Although unamplified 
  107 
ssDNA oligos may be purified along with dsDNA during PCR clean-up, 
contaminating ssDNA will be unable to participate in subsequent restriction digest 
and ligation steps (Horspool et al., 2010; Nishigaki et al., 1985). Thus, It is highly 
unlikely that contamination from other MPRA experimental subsets will occur. 
4.3.1.2 Barcodes  
CRE-associated barcodes are an essential component of the MPRA methodology. 
Our MPRA library design includes barcodes as part of each oligo, resulting in a 
defined mapping between every cis-regulatory element (CRE) and its associated 
barcodes. Each CRE has multiple barcodes that are used as replicates and 
averaged to mitigate potential effects of barcode sequences on transcription and 
mRNA stability. Variations in the 3’ untranslated region (UTR) of mRNA transcripts 
can impact mRNA stability which could alter the barcode counts of MPRA 
experiments (Pesole et al., 2001; Rabani et al., 2017). Having multiple barcodes 
for each CRE has been shown to increase the correlation between MPRA 
replicates (Tewhey et al., 2016); however strong guidelines for the number of 
barcodes to include do not exist.  
Analysis done in Tewhey et al. (2016) suggests that barcode counts up to 50 
barcodes per CRE are beneficial for increasing MPRA replicate correlations; 
however, their MPRA preparation process adds barcodes in a separate emulsion 
PCR step, which requires paired-end HT-sequencing to map CREs to barcodes. 
While this PCR barcoding process increases the number of barcodes that can be 
incorporated into an MPRA library, it may also increase variability at multiple 
protocol steps. Stochastic PCR bias, derived from random templates 
outperforming others in a sequence-independent manner, can result in the loss of 
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barcodes or the increase in variability in separately handled samples (Best et al., 
2015; Smith et al., 2014). This potential increase in variability may account for the 
high suggested barcode count found in Tewhey et al. (2016) in comparison to 
CRE-seq experiments (Fiore and Cohen, 2016; King et al., 2018). 
CRE-seq experiments, where barcodes are included in the initial oligo-pool design, 
have used barcode quantities between 3 - 10 barcodes per CRE (Fiore and Cohen, 
2016; King et al., 2018). Ten barcodes per CRE was suggested to be sufficient for 
MPRA libraries used in cells with a transfection efficiency of 10% - 40%, ensuring 
that at least 4 barcodes were sufficiently represented from the starting 10 (personal 
communication with Cohen Lab). By Including more than the minimum number of 
barcodes we may be able to use the IRF-MPRA design in primary immune cells or 
challenging cell-lines, like THP-1s, assuming a moderate transfection efficiency 
can be reached (Auwerx, 1991; Schnoor et al., 2009).  
Barcodes were designed to avoid sequences that match IRF binding sites and 
restriction enzyme recognition sites used in the MPRA cloning procedures (Acc65I, 
XbaI, BbsI, BsaI, NheI, and more). See chapter 2 for more information. 
4.3.1.3 Vector design and MPRA CRE-library cloning strategy 
Briefly, successful MPRA library generation involves two rounds of restriction 
enzyme digestion and ligation; the first inserts the CRE-library, the second inserts 
the open reading frame (ORF) containing a minimal promoter and eGFP gene. 
Each round of MPRA library cloning requires large scale colony picking (>15,000 
colonies; see Chapter 2 - Methods) and plasmid DNA purification to ensure full 
representation of all CRE plasmids. 
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Vector design is an important component of experiments that require large scale 
cloning. One limitation of existing CRE-seq implementations are the cloning 
efficiencies and the chance of “background” contaminating vector which does not 
contain an insert. To address these concerns, we generated a modified MPRA 
reporter vector (pNL-MPRA) that is designed to reduce background vector 
contamination. First, we opted to include a ccdB death gene cassette (Bernard et 
al., 1994; Dao-Thi et al., 2005; Hu et al., 2010), which is removed during CRE 
insertion, to remove background during the first cloning step (Figure 4.4). Second, 
we adapted the starting reporter vector (pNL3.1; see Chapter 2 for more details) 
to be compatible with asymmetrical type-IIS restriction enzymes for CRE insertion 
and ORF insertion. Type-IIS restriction sites were selected for cloning steps 
because they allow for efficient, simultaneous restriction digest and ligation 
reactions that proceed to an indigestible end product that lacks the initial restriction 
enzyme site (Pingoud et al., 2014, 2005; Roberts, 2003). This processive 
restriction/ligation reaction design has been used widely in synthetic biology and 
complex DNA assembly (Andreou and Nakayama, 2018; Engler and Marillonnet, 
2013; Iverson et al., 2016; Werner et al., 2014). 
4.3.2 Unique Molecular Identifiers and MPRA sequencing library 
preparation 
4.3.2.1 Rationale for Unique Molecular Identifiers (UMIs) 
Accurate quantitation of high-throughput sequencing (HTS) is essential for 
MPRAs. MPRA experiments use barcode counts from raw high-throughput 
sequencing (HTS) reads to measure the transcriptional activity of different CRE 
constructs. Ideally, sequenced barcode counts represent the barcode abundances 
from a starting experimental sample; however, sources of bias and variation during 
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HTS library preparation may lead to inaccurate quantitation. These technical 
errors, when coupled with PCR based amplification, distort the relationship 
between the starting composition of an experimental mRNA/DNA sample and the 
resulting HTS data. Methods to measure and mitigate bias in quantitative HTS 
experiments exist, but have not been implemented for MPRAs (Alon et al., 2011; 
Marx, 2017; Zheng et al., 2011). Here, we briefly discuss sources of HTS bias and 
propose a technical solution adapted to MPRA protocols. 
During HTS library preparation two sources of bias influence the composition of 
sequencing reads that may negatively impact MPRA barcode quantitation. HTS 
library preparation is known to bias sequencing data through sequence dependent 
and stochastic processes (Best et al., 2015; van Dijk et al., 2014). Sequence 
dependent bias may result from differences in PCR amplification stemming from 
properties such as GC content or even context specific bias in polymerase 
efficiency (Thielecke et al., 2017). In clonal cell population experiments, with 
similar conditions to MPRAs, differences between barcode sequences have been 
found to bias barcode counts (Thielecke et al., 2017). This illustrates the influence 
that small sequence differences can have on HTS read composition, and 
emphasizes the importance of having multiple barcodes per MPRA CRE as within-
sample replicates. Although having multiple barcodes per MPRA CRE may 
improve data reliability through averaging, it does not fundamentally address 
problems with HTS read quantitation nor stochastic sources of bias.  
Multiple studies suggest that stochastic processes during PCR, where PCR 
composition becomes biased due to random, sequence-independent differences 
in template amplification, may be a primary driver of skewed HTS library 
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composition (Best et al., 2015; Kebschull and Zador, 2015). Best (2015) found that 
heterogeneous amplification efficiency during HTS protocols stemmed from 
stochastic variation in early cycles of PCR. In their studies of T-cell receptor 
repertoire, small differences in template abundance and amplification efficiency in 
the initial cycles of PCR led to appreciable heterogeneity in HTS read composition 
across replicates and samples (Best et al., 2015). As mentioned previously, the 
DNA duplication inherent in HTS library preparation coupled with sequence 
dependent and stochastic sources of bias may distort the relationship between the 
initial mRNA/DNA template composition and resulting HTS barcode counts. This 
is especially problematic for MPRAs, because they rely on two HTS measurements 
(mRNA and plasmid DNA) to normalize CRE barcode counts (Fiore and Cohen, 
2016; King et al., 2018; White, 2015). Tracking the initial sample composition 
through PCR amplification may improve MPRA quantitation and has been 
implemented for single-cell RNA sequencing using unique molecular identifiers 
(Hashimshony et al., 2016; Islam et al., 2014). 
Multiple single-cell RNA-sequencing (scRNA-seq) protocols use Unique Molecular 
Identifiers (UMIs) to address sources of PCR bias by tagging every mRNA 
molecule at the beginning of HTS library preparation (Bageritz and Raddi, 2019; 
Hashimshony et al., 2016; Islam et al., 2014; Jaitin et al., 2014; Ziegenhain et al., 
2017). UMIs improve HTS quantitation and measure amplification bias by tracking 
PCR duplication events: individual copies of the same mRNA/DNA will receive 
different UMIs such that copies of identical starting material can be distinguished 
from PCR duplicates which will share the same UMI. In RNA-seq, UMIs are often 
random sequences, 5 to 20 nucleotides in length, that are added to each mRNA 
molecule during cDNA first-strand synthesis while some methods add UMIs to 
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sequencing adapters (Hong and Gresham, 2017; Islam et al., 2014; MacConaill et 
al., 2018; Pflug and von Haeseler, 2018). In the technical solution proposed below, 
we add UMIs during both cDNA synthesis and adapter ligation to track bias 
independently at each PCR step. 
UMIs are acknowledged as a way to improve the accuracy of MPRA barcode 
counts and detect PCR amplification bias (Best et al., 2015; Kinney and 
McCandlish, 2019; Ogawa et al., 2017; Smith et al., 2017); however, to date, no 
published MPRA experiment has included UMIs. Implementing UMIs for MPRA 
experiments requires modifications to existing MPRA and HTS library preparation 
protocols. These modifications must work for both mRNA and plasmid DNA 
derived HTS libraries, which specifically excludes many UMI tagging methods 
used in scRNA-seq targeted for mRNA labeling (Islam et al., 2014; Ziegenhain et 
al., 2017). The impact of PCR bias on MPRA HTS library preparation has not been 
measured and the inclusion of UMIs in MPRA experiments may improve barcode 
quantitation. Below we propose protocol modifications that will allow UMI tagging 
of samples from both MPRA mRNA and plasmid pools. 
4.3.2.2 Standard HTS library preparation and CRE-seq protocols are 
incompatible with UMIs 
Standard protocols for HTS library preparation are inefficient for MPRA 
experiments and incompatible with UMI incorporation. Standard Illumina 
sequencing protocols are designed to provide uniform coverage of input mRNA 
and DNA samples (NEB and Illumina promotional materials). Standard HTS library 
preparation often relies on random primer cDNA synthesis and library 
fragmentation before adapter ligation. While these steps provide uniform 
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sequencing coverage, they are incompatible with UMI incorporation due to the lack 
of UMI incorporation into the initial cDNA synthesis process. Additionally, 
sequencing MPRA experiments requires a targeted sequencing strategy, where 
regions of interest are selectivity amplified for sequencing, to obtain the greatest 
data yields. For example, MPRA plasmid-derived mRNAs all contain the same 
reporter gene sequence (eGFP) and the barcode region of the mRNA is the only 
experimentally informative portion (Figure 4.4, 4.5). It is therefore inefficient to use 
HTS protocols that will uniformly sequence the eGFP gene as part of the 
sequencing library. 
While the standard CRE-seq protocol from the Cohen lab addresses issues with 
sequencing efficiency it is not compatible with UMIs. In the CRE-seq protocol, 
cDNA reverse transcription is initiated using poly-dT primers that select for poly-A 
tail containing RNA. The resulting single stranded cDNA library is then amplified 
using PCR targeted to the MPRA barcode region. The PCR primers contain 
restriction sites used to add custom illumina sequencing adapters. After adapter 
ligation the HTS library is amplified and enriched for amplicons containing the 
Illumina P5 and P7 adapter sequences. A parallel process is used for plasmid DNA 
(pDNA) HTS library preparation which starts at the barcode region PCR 
amplification step. This process does not allow incorporation of UMIs. Our 
proposed solution is described below. 
4.3.2.3 Proposal for UMI incorporating sequence-specific first-strand DNA 
synthesis from mRNA and plasmid DNA (pDNA)  
Incorporating UMIs into existing CRE-seq methods requires protocol 
modifications. CRE-seq studies to date have generated sequencing libraries using 
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poly-dT primer-based cDNA synthesis followed by sequence-specific amplification 
of the MPRA barcode region. To effectively identify the starting composition of an 
MPRA sample, UMIs must be incorporated into every cDNA during first-strand 
synthesis. To accomplish this, we propose using sequence-specific primers (ss-
primer) targeting the MPRA barcode region to initiate cDNA synthesis (Figure 4.6). 
These ss-primers will contain a trailing 5-bp UMI and restriction site-containing 
segment used for PCR enrichment and adapter ligation. A second primer targeted 
to a portion of the eGFP coding sequence will be used to incorporate the other 
required restriction site used for adapter ligation. Enrichment of the restriction site-
containing amplicon can proceed using primers targeting the restriction enzyme 
sites (see figure 4.6). We can use a similar method to add UMIs to MPRA plasmid 
sequencing.  
To incorporate UMIs into pDNA sequencing, we propose a ss-primer strategy that 
begins with a single PCR cycle used to incorporate the UMI sequence and 
restriction site for adapter ligation (see figure 4.6). This process parallels the cDNA 
library preparation process described above with one important modification. To 
prevent circular amplification of the small pNL-MPRA plasmid we propose an initial 
restriction digest of the pDNA sample targeting a site within the CRE/ORF region 
of the MPRA library. In the case of the IRF-MPRA design, a HindIII site is present 
just before the minimal promoter. Just as in the cDNA protocol, the second adapter 
restriction site can be added using a single PCR cycle, then the adapter-ready 
amplicon can be enriched using PCR. 
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4.3.2.4 Additional Sequencing library preparation considerations - Preventing 
UMI oligo carryover during library preparation. 
In experiments that include UMIs, careful control of unwanted library amplification 
is important. In standard cDNA preparation and downstream sequencing library 
construction, small quantities of primer may contaminate subsequent protocol 
steps. For example, the Invitrogen SuperScript IV protocol recommends using an 
unpurified 1st strand synthesis reaction as template material for subsequent 
amplification (See Invitrogen SuperScript IV manual). The unpurified reaction 
contains the synthesized cDNA first-strand as well as any excess primer that was 
not incorporated into the cDNA. In the case of poly-dT cDNA protocols, any excess 
primer will not participate in the sequence-specific amplification of template, 
however it is possible that small quantities of additional full-length (poly-A 
containing) cDNA molecules could be generated during PCR amplification. The 
quantity of this off-target amplification is likely to be small; however, the CRE-seq 
protocol uses many cycles of PCR amplification prior to adapter ligation (21+13 
cycles). As discussed earlier, careful quantitation of MPRA sequencing data is 
essential for accurate interpretation of MPRA experiments. Accidental UMI 
incorporation after the initial 1st strand synthesis complete defeats the intention of 
UMIs as a method of tracking PCR duplication to better estimate barcode counts.  
There are few methods to selectively remove primers without purification. Single-
cell sequencing protocols have used template switching RNA primers to generate 
cDNA without subsequent primer contamination during amplification by elegantly 
relying on the hydrolysis of RNA at high temperature in the presence of magnesium 
ions contained in most polymerase buffers (Islam et al., 2014). Unfortunately, this 
template switching technique only tags cDNA molecules at the 5’ end when using 
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a poly-dT oligo (Islam et al., (2014) (Figure 4.7). A requirement for using UMIs in 
MPRA experiments is that the UMIs must be incorporated adjacent to the CRE-
barcodes so they are included in the sequencing read. This requires that 
sequence-specific primers be used to synthesize the first strand of cDNA which 
means that a template switching RNA oligo strategy cannot be used. Additionally, 
the UMI incorporation techniques used in scRNA-seq protocols are incompatible 
with sequencing MPRA pDNA pools for barcode normalization given the lack of 
reverse transcriptase with template switching properties in standard PCR.  
4.3.2.5 Nonsense-mediated primer exclusion (NOPE) - a solution for UMI primer 
contamination 
Nonsense-mediated primer exclusion (NOPE) is a method recently developed 
which addresses the technical complications of UMI primer contamination during 
sequence-specific cDNA generation (Shagin et al., (2017). The NOPE method 
sequesters first strand synthesis primers preventing additional incorporation of 
UMI oligos during subsequent second-strand synthesis and PCR amplification. 
Three key features allow the NOPE oligo to sequester UMI containing primers: (1) 
a region complementary to the target sequence in the UMI oligo; (2) a modified 
base that prevents 3’ polymerase extension from the oligo; (3) a non-
complementary “non-sense” region that is incorporated to the 3’ end of the UMI-
oligo during PCR (See figure 4.8). In the work by Shagin et al. (2017) the NOPE 
technique was tested with genomic DNA. In the IRF-MPRA experiment, the NOPE 
oligo will be necessary in both mRNA and plasmid DNA sequencing preparation 
due to the carryover of UMI containing oligos in both processes. 
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In Shagin et al. (2017), polymerase extension from the 3’ end of the NOPE oligo 
was inhibited by the addition of a bulky Black-Hole quencher (Millipore Sigma) 
which likely prevented extension through steric hindrance. For the IRF-MPRA 
experiment we propose using an inverted-dT (IDT-DNA) that prevents elongation 
and also has the added benefit of being resistant to 3’ exonuclease activity 
exhibited by high-fidelity proofreading DNA polymerases (Ortigão et al., 1992). If 
oligos are not exonuclease resistant then the NOPE oligos may lose their 
extension inhibiting modifications across PCR cycles which may allow them to 
participate in amplification (Ott and Eckstein, 1987). The other modification that is 
important is the non-complementary “non-sense” tail that is added to each UMI-
oligo. This sequence can vary, but a set of nucleotides with a high AT content may 
reduce the possibility of the non-sense tail mispriming, decreasing the likelihood 
of unwanted polymerization. The NOPE oligo would be added after the initial first 
strand cDNA synthesis step for mRNA samples, or after a single cycle of PCR in 
the case of pDNA, along with the primer for second strand synthesis (see Figure 
4.6). Additional amplification, and selection for full-length target amplicons (those 
with both the R1 and R2 restriction sites), can be performed with additional primers 
corresponding to R1 and R2 sites. Throughout this process, the PCR products that 
are generated from the NOPE-oligo:UMI-oligo duplex will lack the primer site used 
to generate the second strand of cDNA and will fail to be amplified. A similar 
protocol was used in the original NOPE oligo paper (see figure 4.8). 
4.3.2.6 Sequencing library preparation - adapter design and library complexity 
In standard Illumina RNA-seq library preparation, P5 and P7 illumina adapters are 
added to fragmented DNA/cDNA using T/A cloning ligation (Figure 4.9). As part of 
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the CRE-seq protocol, restriction enzyme (RE) sites are included in the 1st and 
2nd strand cDNA synthesis primers (similar to Figure 4.6). The Cohen lab CRE-
seq protocol uses a linear adapter that uses specific restriction digest sites to 
provide end-specificity. In our modified design we use type-IIS BbsI sites to 
generate sticky overhangs for ligation. By using end-specific overhangs we can 
ensure that the ‘Read1’ sequencing primer is ligated to the barcode side of the 
target amplicon which is not the case in standard T/A adapter ligation (Figure 4.9). 
This process guarantees that all sequencing reads will be in the same orientation, 
allowing for efficient use of single-end sequencing reads and maximizing data 
yield.  
As part of the adapter ligation process, we propose including an adapter-UMI 
adjacent to the Illumina ‘Read1’ primer sequence (Figure 4.10). This adapter-UMI 
has two purposes: (1) the UMI allows additional tracking of PCR duplication events 
after adapter ligation. Similar strategies have been used in other studies (Hong 
and Gresham, 2017; MacConaill et al., 2018; Pflug and von Haeseler, 2018). (2) 
This UMI will improve sequencing by increasing library complexity. MPRAs involve 
sequencing highly similar pools of RNA and DNA. Illumina sequencing machines 
use the first ~5 bases of sequencing to visually distinguish sequence clusters 
(Figure 4.11) (2011). This process requires sufficient representation of all 
nucleotides at each sequenced base during cluster calling. Krueger (2011) found 
that considerable sequencing data were automatically discarded by the Illumina 
sequencing platform due to low sequence complexity. One recommended way to 
increase sequence diversity is to spike-in Phi-X lambda phage genome standards 
(Illumina). Phi-X concentrations of 20-30% of total DNA are recommended by the 
Cohen Lab CRE-seq protocol, which is a sizable portion of an expensive 
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sequencing lane. By including a random UMI in our adapter design, the resulting 
increase in sequence diversity may allow significantly less Phi-X spike-in to be 
used; however, empirical tests will be required to optimize conditions. 
One manufacturing complication arises from the inclusion of a random UMI in our 
adapter design, but is easily solved. Correctly annealing random oligos is 
recognized as a physically improbable process (Oliphant et al., 1986). In the case 
of sequencing UMIs it is incredibly important that both strands of the adapter have 
identical sequences so that UMI diversity is not over-estimated. Preliminary 
designs for the UMI sequencing adapter used a single stranded DNA oligo to avoid 
the random annealing problem. This strategy assumed that dsDNA-ssDNA ligation 
by T4 DNA ligase would be equivalent to a dsDNA-nick repair and highly efficient. 
Research by Horspool et al. (Horspool et al., 2010) found that T4 DNA ligase 
required a double-stranded duplex at the site of ligation of at least 5 bp for effective 
ligation with the greatest efficiency at a length of 6bp or greater (Horspool et al., 
2010). This context directly parallels our MPRA sequencing adapter ligation and in 
light of these data, we propose a modified semi-dsDNA adapter that includes a 6 
bp constant sequence adjacent to the ligation site followed by the ssDNA UMI and 
remaining adapter (Figure 4.10). This strategy will likely solve both the UMI 
annealing and the T4 ligase efficiency problems; however, empirical tests of this 
modification will be required. This design reduces the cost of sequencing adapters, 
which are recommended to include an exonuclease resistant 3’ modification and 
be purified to a higher standard than desalted oligos (NEB and IDT-DNA 
recommendations). The constant region in this adapter design could also be used 
for additional sample multiplexing if multiple sets of adapters were ordered. Also, 
greater sequencing read base diversity could be achieved by varying the length of 
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the constant duplex-region to change the sequencing phase of different samples, 
thus increasing the complexity of an individual base position. 
Lastly, our custom UMI adapter design uses a two-step adapter extension process 
paralleling that used by the NEBnext library workflow (Figure 4.12). In the NEBnext 
protocol, truncated adapters are ligated on to the prepared DNA library, then a final 
PCR step with primers (containing the complete Illumina adapters) is used to 
amplify the library. This two step adapter preparation step allows for the inclusion 
of multiplexing indices in the P7-index region of the Illumina adapter (Figure 4.12 
and 4.10 ). In the Cohen lab CRE-seq protocol, they use inline sample multiplexing 
indices that occupy sequencing read space. This two-step adapter preparation 
allows for standard NEBnext index sets to be used for sample multiplexing easily 
expanding the number of replicates and samples that can simultaneously be 
sequenced.  
4.3.2.7 Preliminary IRF-MPRA library sequencing 
In an effort to verify the integrity of the IRF-MPRA library and assess barcode 
representation after CRE insertion into the pNL-MPRA backbone, the IRF-MPRA 
library was sequenced using the MGH sequencing core amplicon sequencing 
service. 150,226 paired-end reads, with 75,113 pairs, were obtained from the IRF-
MPRA CRE-insert library (See summary Table 4.1). 71,476 barcodes were 
successfully extracted from the raw sequencing reads with 94.9% (67,866) of 
these barcodes identically matched designed barcodes. 3,610 extracted barcodes 
did not match the designed barcode list, and likely represent sequencing errors. 
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3,159 of 3,160 barcodes were represented in the sequencing data and replicate 
sequencing may verify the presence of all barcodes in the MPRA library. The mean 
number of reads per barcode was 21.5 reads/barcode with a minimum of 0 and a 
maximum of 60 reads/barcode. The distribution of read/barcode frequencies was 
unimodal and comparison of the mean (21.5) and median (21) does not suggest a 
skewed distribution (see Table 4.2 and Figure 4.13). These data suggest that there 
is sufficient barcode representation in the IRF-MPRA CRE insertion library to 
proceed with ORF cloning. 
4.4 Conclusion 
To assay the sequence determinants of IRF-dependent transcriptional regulation, 
we proposed using a modified massively parallel reporter assay (MPRA). MPRAs 
use high-throughput sequencing to measure the transcriptional activity of many 
thousands of cis-regulatory elements (CREs) at once. In this chapter we detail 
modifications to the MPRA technique that may improve key steps in the MPRA 
library cloning process and improve MPRA high-throughput sequencing. The 
proposed MPRA modifications leverage unique molecular identifiers to improve 
accuracy of reporter gene quantitation. The experiments and techniques proposed 
lay groundwork for future studies of IRF-dependent transcriptional regulation.  
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Figure 4.1 - The IRF-MPRA design includes Single Nucleotide Variants (SNV) for a subset 
of IRF binding sites. 
A) Diagram of SNV probe generation process used for the IRF-MPRA design. 
SNV probes begin with a seed probe which is used to generate all possible 
single base substitutions along that seed sequence. B) List of all PBM derived 
binding sites used for SNV experiments in the IRF-MPRA design. Underlined 
regions highlight key differences between the binding sites. The underlined 
regions in the first two probes highlight the differences in the sequences flanking 
the IRF binding site. The core half sites of the 3rd sequence feature non-
canonical 5’-GATA-3’ sites. The 4th sequence features a 3 base pair spacer 
between the core half sites. 
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Figure 4.2 - The IRF-MPRA design features Cis-Regulatory Elements based on the 
interferon Viral Response Elements. 
(A)The type-I-interferons feature a conserved CRE called the Viral Response 
Element consisting of multiple IRF binding sites. (B)We substitute IRF binding 
sites of interest into the existing IFNα-14 context at the VRE-C and VRE-D sites. 
(C) As part of the MPRA design we include non-SNV sites that were assayed in 
our IRF3/5/7 PBMs.  
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Figure 4.3 - Diagram of IRF-MPRA experimental subsets 
Our MPRA features multiple binding site layouts. The viral response element subset features two 
IRF binding sites separated by a spacer. The ablation layout substitutes the “null” sequence for 
each binding site position as illustrated with red-X’s. We test the effect of binding site orientation 
by reverse-complimenting the IRF binding sites. Lastly, we include a variable spacer design. 
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Figure 4.4 - MPRA experimental workflow 
MPRA experiments begin with an MPRA pool and an empty destination vector. 
The CRE insertion step uses restriction digest and ligation to insert the CRE 
cassette from the MRA pool into the destination vector. Next, an open reading 
frame (ORF) that contains a minimal promoter and eGFP gene is inserted into 
the CRE containing vector pool. This library is then grown a large scale and 
purified before transfection into cells. MPRA plasmid and mRNA is isolated from 
transfected cells and processed for high-throughput sequencing. 
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Figure 4.5 - MPRA CRE insert architecture 
Sequence diagram of the IRF-MPRA CRE insert design. The CRE is inserted 
into the pNL-MPRA backbone using Acc65I and XbaI sites. This is followed by 
ORF insertion using BbsI sites. A SnaBI site is present to linearize any remaining 
ORF insert library that did not receive an ORF during cloning. 
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Figure 4.6 - umiCRE-seq protocol workflow 
Isolated MPRA plasmid DNA (pDNA) or mRNA have similar workflows. First UMIs (UMI1) are 
incorporated via a 1st strand synthesis step using a reverse transcriptase (mRNA) or single cycle 
PCR reaction (pDNA). An adapter ligation restriction site is included in this step (R1). Next, 
second-strand amplification primers are added that contain a second adapter ligation site (R2), as 
well as R1 containing amplification primers. NOPE oligos are added to sequester any remaining 
UMI containing primer. Next, the amplified sample is restriction digested and adapters are ligated. 
The adapter closest to the MPRA barcode contains a second UMI (UMI2). Both adapters contain 
NEB sequencing primers that allow NEBnext multiplexing kits to be used for sample labeling. 
Finally using the NEB mutiplexing primers, the library is amplified and then finished using the 
standard illumina P5 and P7 primers.  
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Figure 4.7 - scRNA-seq UMI addition schematic 
Schematic of UMI incorporation procedure used for scRNA-seq from Islam et al. 
(2014). This process is incompatible with pDNA as it relies on RNA hydrolysis to 
remove unincorporated primers and it also requires a template-switching enzyme 
(i.e. reverse transcriptase). Taken from Islam et al. (2014) 
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Figure 4.8 - NOPE workflow schematic 
Taken from Shagin et al. (2017). NOPE oligos neutralize UMI-primers by 
sequestering them and preventing PCR extension. NOPE are complementary to 
the gene specific annealing region present in the UMI containing amplification 
primer. An essential component of the NOPE process is a “nonsense” region 
present in the NOPE oligo that prevents sequence specific annealing once the 
NOPE oligo has been incorporated into excess UMI primer during PCR. An oligo 
modification on the NOPE oligo also prevents extension of the UMI primers. 
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Figure 4.9 - Illumina sequencing library workflow 
Illumina sequencing uses fragmented starting DNA and T/A ligation which are 
incompatible with Unique Molecular Identifiers and inefficient for MPRA 
experiments. T/A ligation utilizes single nucleotide base pair overhangs to add 
adapters to the sequencing library. Modified from Illumina.com 
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Figure 4.10 - Diagram of the proposed UMI containing sequencing adapter. 
Graphical depiction of the partially double-stranded UMI containing adapter. The 
double-stranded constant annealing site allows for efficient T4 ligase activity 
when ligating this adapter to the restriction digested MPRA library.  The direction 
of the sequencing read is indicated beneath the Read 1 region. 
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Figure 4.11 - Successful cluster differentiation requires nucleotide diversity 
Low complexity samples can lead to problems with cluster differentiation leading 
to loss of sequencing data. This figure illustrates the challenge of low diversity 
samples during early cluster calling sequencing cycles. Circles represent 
sequencing clusters on an Illumina flow cell. Enlarged cluster circles present in 
cycles 1-4 illustrate how the Illumina sequencing machine may fail to differentiate 
adjacent clusters that share the same base call during a cycle. Adjacent clusters 
that look the same cannot be differentiated by the sequencing machine and are 
discarded as bad data. This illustrates the need for diverse samples. Modified 
from Krueger et al. (2011) 
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Figure 4.12 - Overview of NEBnext library preparation 
NEBnext uses a two-step adapter addition process that allows for straightforward 
sample multiplexing. Our custom MPRA adapters are compatible with standard 
NEBnext multiplexing indices. Adapter ligated MPRA sequencing libraries could 
utilize NEB components used in the PCR enrichment step onward. During PCR 
enrichment, multiplexing indices can be added to different samples. Adapted 
from NEB.com 
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Figure 4.13 - Histogram of preliminary MPRA library sequencing data. 
Histogram showing the frequency of barcode counts (i.e. count of barcode 
counts). Each bar displays the number of retrieved barcodes that contain a given 
number of sequencing reads. For example, 154 barcodes had a sequencing read 
count of 19 reads per barcode. 
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Table 4.4.1 – Summary table of MPRA library preliminary barcode sequencing. 
For quality control, we sequenced the initial CRE insertion MPRA library. MGH sequencing core 
Illumina paired end sequencing resulted in 150,226 reads sorted into 75,113 pairs. From these 
data we extracted 71,476 barcodes with 67,866 of them matching our designed sequences, 3610 
extracted barcodes deviated from the expected sequences. 
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Table 4.4.2 – Sequence read per barcode descriptive statistics 
Preliminary MPRA library quality control sequencing resulted in retrieval of 3,160 barcodes. The 
mean number of sequencing reads per barcode was 21 per barcode (SD ± 8.79). One barcode of 
the designed 3161 barcodes was not retrieved from sequencing. 
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5 CHAPTER FIVE 
5.1 Summary of findings 
IRF3/5/7 are central regulators of the host-defense program to pathogens (Honda 
and Taniguchi, 2006; Lazear et al., 2013; Stetson and Medzhitov, 2006a). IRF3/5/7 
are homologous transcription factors with highly-conserved DNA-binding domains 
and can all bind the consensus IRF binding site (5’-GAAANNGAAA-3’). Despite 
their ability to bind the same consensus sequence, IRF3/5/7 drive overlapping and 
distinct gene programs.  
In Chapter 3, using PBMs we assessed the ability of inherent IRF3/5/7 DNA-
binding differences to define dimer-specific gene regulation. The differences we 
found provide a mechanism for explaining the differential IRF-dependent 
regulation of immune genes. We characterized the DNA-binding preferences of 
IRF3/5/7 homodimers, and demonstrated that dimer-specific binding can promote 
dimer-specific gene expression. These results support the claim that DNA-binding 
differences between IRF3/5/7 are sufficient to induce unique target gene sets. For 
example, we found that IRF5 is largely excluded from binding IRF regulatory 
elements from the human and mouse IFNα promoters. This conserved exclusion 
is mediated by selection against specific sequences by IRF5. Mutational analysis 
of IRF5 and IRF7 found a single amino acid residue that contributes to this binding 
selectivity. Lastly, we found evidence of clear affinity-independent mechanisms in 
IRF-dependent gene regulation. More specifically, we found that DNA sequence 
features in IRF binding sites can enhance reporter gene activity at the expense of 
binding affinity. These expression modulating sequence features can be regions 
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flanking the core IRF motif and may have implications for our understanding of 
IRF-dependent gene regulation as a whole. 
In Chapter 4, we propose a modified Massively Parallel Reporter Assay (MPRA) 
protocol that utilizes Unique Molecular Identifiers (UMIs) to increase the potential 
quantifiability of MPRAs. We describe key technical hurdles and address these 
issues with proposed solutions. The groundwork provided in chapter 4 provides a 
foundation for future graduate research. 
5.2 Discussion 
5.2.1 IRF-dependent gene regulation 
Our PBM data in Chapter 3 shows clear DNA-binding differences between 
IRF3/5/7. Each IRF maintains the ability to bind the same common IRF binding 
site (5’-CCGAAACCGAAACC-3’) while differentially tolerating deviations from 
this high-affinity IRF-site. Our reporter data found that preferential IRF-binding to 
IRF-sites can drive reporter gene expression in an IRF-homolog specific manner. 
For example, IRF3 specific binding sites only drove reporter gene expression in 
cells over expressing phosphomimetic IRF3. This suggests that sequence 
differences in IRF binding sites are sufficient to drive gene expression in an IRF-
homolog specific manner. Despite the fact that binding affinity does not appear to 
predict the expression level in our reporter assays, the absence of binding (i.e., 
the inability of IRF7 or IRF5 to bind to our IRF3-specific site) appears to predict 
the inability to drive reporter gene expression. Therefore, we conclude based on 
our PBM data that IRF3 and IRF7 can regulate the type-I-interferons (IFNα and 
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IFNβ) as well as CXCL10, and IL10, which is consistent with the existing 
literature (Honda and Taniguchi, 2006)  
As summarized above, IRF5 was shown to not bind the human IFNα VRE 
regions with strong affinity, suggesting that IRF5 homodimers may not directly 
regulate the IFNα genes. It is possible that aggregate, low affinity DNA binding 
by IRF5 to the IFNα promoters could drive gene expression a mechanism which 
has been shown for other TFs (Crocker et al., 2015). In Chapter 3 we see that 
IRF5 shows appreciable binding to some of the mouse IFNα promoters, 
suggesting that the role of IRF5 in IFNα regulation may differ between humans 
and mice, potentially complicating the combined interpretation of human and 
mouse derived data across the field. We also find that IRF5 binds to the IFNβ 
promoter sequences and IRF5 has been shown to induce IFNβ production (del 
Fresno et al., 2013). Given this, IRF5 may indirectly induce the expression of 
IFNα genes via production of IFNβ which activates the ISGF3 TF complex 
(STAT1-STAT2-IRF9) through the Interferon receptor (Fink and Grandvaux, 
2013). ISGF3 is known to bind ISREs (Cheon et al., 2013) and activation of this 
complex, downstream of IRF5 induced IFNβ signaling, could contribute to IFNα 
gene expression. Many viruses impair IRF-dependent gene activation as a 
mechanism of infection, making cross-talk between anti-pathogen signaling 
pathways an important component of a robust immune response (Chan and 
Gack, 2016; Fensterl et al., 2015; Kawai and Akira, 2011). It has been suggested 
that IRF5 binding may be facilitated by RelA and that IRF5 may also be indirectly 
recruited to RelA binding sites (Saliba et al., 2014). This mechanism could 
provide another route for IRF5 activation to contribute to the interferon response. 
  147 
Interactions between IRF homologs both through heterodimerization and 
potential competition for binding sites is an additional layer of IRF-dependent 
gene regulation. As discussed in Chapter 3 (Section 3.3 - Limitations), IRF3/5/7 
heterodimerization is an important aspect of IRF-dependent gene regulation. 
Heterodimerization is a mechanism that could expand the DNA-binding repertoire 
of the IRFs, notably IRF5. IRF3+7 heterodimers are thought to contribute to the 
temporal dynamics of IFNα expression during the anti-viral response with the 
ratio of IRF3:IRF3+7:IRF7 regulating which set of IFNα genes are expressed at a 
given time (Genin et al., 2009a). Future experiments to understand IRF 
heterodimerization may be able to use both purified or endogenously activated 
IRFs (nextPBM) to study heterodimer DNA-binding specificity. However, these 
experiments will need to establish the stability of IRF heterodimers, potentially 
using EMSAs or native westerns to assess the fraction of heterodimer to 
homodimer. IRF3/5/7 have been described to function as both transcriptional 
activators and repressors in different promoter contexts (Barnes et al., 2002b; 
Honda et al., 2006). Competition between IRFs at IRF binding sites, in 
conjunction with differential recruitment of transcriptional activators and 
repressors (discussed below), may contribute to these dichotomous regulatory 
effects. Unfortunately, research in the Siggers lab suggests PBMs are not able to 
assess competition in protein binding, but traditional competition EMSAs may 
provide insight for sequences of interest. 
As mentioned above, Saliba et al. (2014) and Krausgruber et al. (2010) suggest 
that IRF5 and RelA interact at multiple pro-inflammatory gene promoters (TNFα, 
IL-6, IL-1a) after LPS stimulation in macrophages (Saliba et al., 2014). This is an 
interaction that the authors suggest could explain the dual role of IRF5 as an 
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activator and inhibitor of gene expression. IRF5 ChIP-seq data and motif analysis 
from Saliba et al. (2014) fails to retrieve canonical ISRE motif, but suggests that 
IRF5 may bind a composite ETS-IRF site with PU.1; although, the ETS-IRF site 
may be utilized by multiple ETS factors in addition to PU.1. IRF4 and IRF8 are 
known to bind both ETS-IRF and NFAT-IRF composite elements cooperatively 
with PU.1 or NFATc2 respectively. If IRF5 interacts cooperatively with ETS 
factors, in a similar manner to IRF4 and IRF8, then this would be an additional 
mechanism of IRF5dependent gene regulation. In our PBM data, IRF5 shows a 
strong binding preference for the 3’ half site of the ISRE with little specificity in 
the 5’ half site, which is consistent with previous data sets Jolma:2013fh}. The 
decreased specificity present in the PBM-derived IRF5 motif corresponds to the 
ETS portion of the ETS-IRF motif found by Saliba et al. (2014) in IRF5 only ChIP-
seq peaks. Given this, IRF5 may be able to use non-ISRE type binding sites as 
an asymmetric homodimer, or in conjunction with other binding partners. In this 
context, IRF5 may compete for occupancy of PU.1:IRF4 or IRF8 binding sites. 
Interestingly, IRF4 and IRF5 have been shown to compete for access to the 
MyD88 adapter protein down stream of TLR signaling which could provide 
additional layers of regulation in a cell-type and stimulus-specific manner. 
5.2.2 Evolution of the IRFs and IFNα 
IRF DNA-binding domains (DBDs) are highly conserved across many species 
(Figure 5.1). The conserved amino acids include the lysine residue (IRF5 K96) 
shown to contribute to the specificity of IRF5 seen in our PBM data. In Chapter 3, 
we note that the exclusion of IRF5 binding at the IFNα promoter sequences on 
our PBM is evolutionarily conserved between human and mouse, resulting from a 
nearly complete absence of cytosine bases flanking the IRF 5’-GAAA-3’ core that 
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are both highly preferred by IRF5. A more in-depth phylogenetic analysis of the 
type-I-interferon gene promoters is complicated by a complex evolutionary 
history involving both gene conversion and gene duplication (Krause and Pestka, 
2015; Redmond et al., 2019; Xu et al., 2013), making precise inference about the 
evolution of IRF sites in these promoters prohibitively difficult.  However, there 
are multiple genes in human and mouse that are known targets of IRF3/5/7 that 
have 5’-CGAAAC-3’ containing ISREs as evident in our PBM data (IFNβ, 
CXCL10, IL10) and the literature (Koshiba et al., 2013). A single base-pair 
mutation of a 5’-GAAA-3’ flanking cytosine would allow IRF5 binding and 
maintain IRF3/7 binding to that site. If the immune role of IRF5 is to drive a 
distinct pro-inflammatory gene program as suggested in the literature (Saliba et 
al., 2014; Weiss et al., 2015), then maintaining regulatory separation between 
IRF3/7 (anti-viral response) and IRF5 (inflammatory response) may be 
evolutionarily advantageous. Our findings that IRF5 homodimers do not bind 
strongly to the IFNα promoters of human and mice suggests an evolutionarily 
conserved mechanism to distinguish these homodimers that is not shared across 
all IRF-dependent genes. Future studies that directly examine the possible 
alternative IRF5-containing complexes will be important to understand its 
conserved role in IFNα gene regulation.  
5.2.3 Potential mechanisms of affinity-independent ISRE function 
As summarized above, we found clear evidence of affinity-independent 
mechanisms of IRF transcriptional regulation. Understanding the relationship 
between TF DNA-binding and transcriptional activity is an important pursuit in 
molecular biology. A complete mechanistic description of IRF-dependent gene 
  150 
regulation is beyond the scope of this dissertation, but there are many avenues for 
future work. 
As mentioned in Chapter 3, mechanisms for DNA-sequence-based allosteric 
regulation of transcription factors have been described for multiple TFs (Mazumder 
et al., 2017; Watson et al., 2013). A structural feature of the IRF transcription 
factors that may play a role in allosteric regulation is a minor-groove contacting 
loop (L1) of the IRF DBD which contacts DNA bases adjacent to the core GAAA 
(De Ioannes et al., 2011; Panne et al., 2007) This loop has been shown to change 
conformation between a DNA bound state and unbound state and a conserved 
histidine in this loop (hIRF3-H40; hIRF5-H49; hIRF7-H46) makes contacts with the 
5’ A:T bases in the IRF binding sequence (De Ioannes et al., 2011a; Shukla et al., 
2012). Given this important structural feature, changes in flanking sequence could 
alter IRF DBD conformation impacting the overall structure of a dimeric IRF 
complex. DNA sequence based allostery described for the glucocorticoid receptor 
(GR) involves a structural transmission of the DNA sequence readout through the 
dimerization interface of the GR complex, ultimately leading to differential trans-
activation potential (Meijsing et al., 2009; Watson et al., 2013). Although the crystal 
structure for a full-length IRF protein has not been solved, the IRFs have two well-
structured domains (the DBD and the IAD/AID) that are connected together by a 
linker that is suggested to be semi-structured. Linkers between modular protein 
domains are capable of transmitting allosteric information to influence a protein’s 
function (Ma et al., 2011). Similar to GR, subtle allosteric perturbations from DNA 
sequence binding may alter the conformation or dynamics of the IRF C-terminal 
protein association domains thus impacting the recruitment of transcriptional 
activators such as CBP and p300. 
  151 
A speculative model that does not require specific allosteric changes to IRF 
structural conformation, is a dynamic model where lower-affinity, asymmetric 
binding to a dimeric IRF site increases the accessibility of an IRF dimer’s 
transactivation domain. In this model, one monomer of the IRF dimer anchors the 
complex to the DNA while the other facilitates interactions with other proteins via 
greater binding flexibility due to lower affinity DNA interactions. In our PBM 
experiments, we found some evidence for asymmetric sequence specificity in IRF 
binding logos, where the 5’ region of the IRF binding site outside of the core had 
moderately decreased information content. This decrease in specificity could allow 
more dynamic associations with DNA and cofactors, while not wholly disrupting 
IRF dimer binding. Given the lack of a full-length IRF crystal structure, it is unclear 
how the dimerized IRF association domains are oriented in relation to the IRF DBD 
and how a decrease in binding affinity might influence co-factor recruitment. 
Determination of a full-length IRF crystal structure would greatly advance IRF-
related research on innate immune regulation.  
5.2.4 IRF-dependent transcriptional regulation and cofactors 
Transcriptional regulation is a multifaceted process that integrates TF DNA-
binding, higher order protein-protein interactions, and epigenetic differences in the 
chromatin landscape. Understanding this complex cellular process is beyond the 
scope of the work in this dissertation; however, we have made progress by 
describing key differences in the IRF DNA-binding landscape.  
Elucidating how sequence dependent differences in TF-DNA binding may alter 
cofactor recruitment is an important next step in understanding innate immune 
regulation. Recruitment of transcriptional activators like CBP, or repressors like 
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NCoR have been shown to play an important role in IRF-dependent gene 
regulation (Caillaud et al., 2002; Chen et al., 2008a; Feng et al., 2010). The role of 
competing inputs, coactivators versus corepressors, in IRF driven gene expression 
is not well understood. IRF3, IRF5 and IRF7 have been shown to interact with the 
coactivator CBP (Caillaud et al., 2002; Chen et al., 2008a), with x-ray 
crystallography evidence for the IRF3-CBP interaction (Qin et al., 2005). IRF5 has 
shown to interact with the corepressor NCoR/Sin3a/SMRT (Feng et al., 2010) as 
well as KAP1/Trim28 (Eames et al., 2012). Interestingly, the Trim28-IRF5 
interaction described by Eames et al. (2012) was shown to be mediated by the 
unstructured linker between the IRF5 DBD and IRF association domain (IAD). This 
provides a potential mechanism for IRFs to function both as repressors or 
activators of transcription. Speculatively, it is possible that an integration of these 
activating/inhibiting states is responsible for the affinity-independent regulation of 
transcription seen in chapter 3. 
5.2.5 Outstanding questions and future work 
IRF-dependent gene regulation is complex and involves multiple layers of 
regulation. The research in this thesis set out to characterize intrinsic differences 
between IRF3/5/7 in order to better understand protein-DNA binding, a 
foundational layer of gene regulation. Open questions of interest include: 1) How 
do IRF heterodimers coordinately regulate IRF target-genes? 2) How do IRF3/5/7 
differ in their ability to recruit cofactors, and what cofactors do the interact with? 3) 
What model best explains the relationship between IRF DNA-binding and IRF-
dependent gene regulation? 4) How do differences in IRF-DNA binding influence 
diseases such as Systemic Lupus Erythmatosus, where IRF disregulation is 
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associated with disease risk? These questions may be starting points for future 
research in the field of IRF-dependent gene regulation. 
The MPRA experiments proposed in Chapter 4 provide a platform for investigating 
the relationship between DNA sequence and transcriptional activity. It is likely that 
systematic investigation of how variations in IRF binding sites can impact 
transcription can be integrated with DNA binding data, such as presented here, to 
define the relationship between binding and activity. By looking for MPRA CREs 
that violate simple models of transcription factor binding and transcriptional activity 
we may identify interesting exceptions to explore. Follow up could include DNA-
protein pull-down assays to identify members of DNA bound regulatory complexes. 
MPRAs performed by Grossman et al. (2017) used immunopreciptation to pull-
down and sequence MPRA plasmids bound by PPARɣ. This process could be 
performed with modification to identify other members in the DNA-binding complex 
after initial immunoprecipitation using a panel of antibodies. After careful, 
biochemical analysis, high-interest CREs could be further explored using X-ray 
crystallography or Cryo-EM to resolve in high-order protein complexes (Nogales, 
Scheres, 2015). 
Future work toward understanding IRF3/5/7 transcriptional regulation could also 
utilize recently developed nuclear extract PBMs (nextPBMs) (Mohaghegh et al., 
2019) and cofactor recruitment PBMs (currently in development in the Siggers lab). 
These exciting new methods provide a platform for investigating the DNA-
sequence dependence of higher-order protein-complex assembly. Biochemical 
studies using IRF3/5/7 constructs with mutated linker regions expressed in 
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mammalian cells could be used to explore potential interactions between DNA-
sequence and protein-structure in a systematic way. 
5.3 Conclusion 
The research in this dissertation was started to better understand the scope of 
IRF3/5/7 DNA-binding differences and their role in defining dimer-specific target 
genes. We used protein-binding microarrays (PBMs) to characterize the DNA-
binding landscape of IRF3/5/7 dimers and identified key differences in DNA-
binding specificity between IRF3, IRF5 and IRF7. We integrated PBM data with 
reporter assay data and found evidence for affinity-independent mechanisms of 
IRF-dependent transcriptional regulation. Here we proposed a modified MPRA 
protocol that incorporates Unique Molecular Identifiers with the potential to improve 
MPRA data quantification. As part of this work we proposed a multipart IRF-MPRA 
experiment designed to explore the relationship between IRF DNA-binding affinity 
and transcriptional regulation. Our results provide new insights into the role and 
limitations of affinity as a distinguishing mechanism of IRF3/5/7 gene expression 
and function, as well as providing groundwork for future work in this field. 
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Figure 5.1 – IRF5 DNA binding domain sequence alignment 
The DNA binding domain (DBD) of IRF5 is highly conserved across evolutionary time. The ⍺3 
alpha helix (blue box), responsible for recognizing the IRF core 5’-GAAA-3’ sequence is nearly 
identical across chicken, zebra fish, coelacanth, human and mouse. The amino acid residue 
partially responsible for the exclusion of IRF5 is identically conserved across all species (purple 
box).  
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